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Bacteria are one of the richest sources of pharmaceutically relevant compounds. 
Nevertheless, the production level of those important compounds in the original hosts is 
often quite low, and sometimes it is so low that we cannot detect them with current 
analytical techniques. Researchers have developed various solutions, such as 
heterologous expression, co-cultivation of different bacteria, optimization of fermentation 
conditions, discovery of new species, engineering of biosynthetic enzymes, and 
manipulating regulatory elements. The main goal of my doctoral dissertation research is 
to engineer natural product biosynthetic pathways for the generation of novel compounds 
and enhanced production of known medicinally valuable compounds. 
I first investigated the glycosylation steps in the biosynthesis of two antifungal 
angucyclines, Sch47554 and Sch47555 using two different strategies. The heterologous 
co-expression of the aglycone and sugar biosynthetic genes with schS7 in Streptomyces 
lividans K4 led to the production of a novel C-glycosylated rabelomycin derivative. Gene 
inactivation of schS9 and schS10 revealed that subsequent glycosylation steps take place 
in a sequential manner in which SchS9 first attaches either a L-aculose or L-amicetose 
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moiety to the 4'-OH of the C-glycosylated aglycone, then SchS10 transfers a L-aculose 
moiety to the 3-OH of the angucycline core. In this research, I isolated two novel 
angucycline derivatives and gained new insights into the glycosylation steps in the 
biosynthesis of Sch47554 and Sch47555. 
Next, I engineered the regulatory elements in Streptomyces sp. SCC-2136 through 
overexpression and targeted gene disruption approaches for enhanced production of 
pharmaceutically important angucyclines. Gene disruption of schA4 and schA16 led to a 
significant increase in the titer of Sch47554, while the titer was dramatically decreased in 
Streptomyces sp. SCC-2136/ΔschA21. Overexpression strains produced consistent results 
with the gene disruption strains. The highest titer of Sch47554 was achieved in 
Streptomyces sp. SCC-2136/ΔschA4 (27.94 mg/L), which is significantly higher than the 
wild type. Further, I confirmed the functions of these three regulatory elements. SchA4 
and SchA16 are repressors, while SchA21 acts as an activator. 
Last, I isolated a carotenoid-producing endophytic bacterium from the leaves of 
Taxus chinensis, which was identified as Pseudomonas sp. 102515 based on the 16S 
rRNA gene sequence. Analysis of its secondary metabolites revealed that this endophytic 
strain produces a major product zeaxanthin diglucoside, a promising antioxidant natural 
product that belongs to the family of carotenoids. Based on the genome of a closely 
related Pseudomonas strain, I amplified a complete carotenoid (Pscrt) biosynthetic gene 
cluster from Pseudomonas sp. 102515. The functions of PsCrtI and PsCrtY in the 
biosynthesis of zeaxanthin diglucoside were characterized as phytoene desaturase and 
lycopene cyclase, respectively. The entire Pscrt biosynthetic gene cluster was 
successfully reconstituted in E. coli BL21(DE3) and Pseudomonas putida KT2440. The 
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engineered strain of P. putida KT2440 produced zeaxanthin diglucoside at 144 ± 4 mg/L 
in SOC medium supplemented with 0.5% glycerol at 23 C, while the titer of zeaxanthin 
diglucoside in E. coli BL21(DE3) was very low. The production of zeaxanthin 
diglucoside in Pseudomonas sp. 102515 was improved through the optimization of 
fermentation conditions such as medium, cultivation temperature and growth time. The 
highest titer under the optimized conditions reached 206 ± 6 mg/L. To further enhance 
the production, I introduced an expression plasmid that harbors the Pscrt biosynthetic 
gene cluster into Pseudomonas sp. 102515, yielding an efficient producing strain of 
zeaxanthin diglucoside. The titer in this engineered strain reached 380 ± 12 mg/L, which 
is 85% higher than the wild type. 
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This dissertation is focused on exploring the potential of bacteria for the 
biosynthesis of natural products with the purposes of generating novel natural product 
derivatives and of improving the titer of pharmaceutically important natural products. 
A wide variety of compounds from various sources have been historically used in 
the treatment and prevention of diseases. Natural products as a major source of new drugs 
are extensively explored due to their huge structural diversity and promising biological 
activities such as antimicrobial, anticancer, antifungal, antiviral and antioxidant 
properties. For instance, penicillin as an early-discovered antimicrobial agent has saved 
millions of lives, indicating the historical importance of natural products. However, the 
alarming rise in the prevalence of drug resistance is a serious threat to public health and it 
has coincided with the decreasing supply of new antibiotics. Bacteria with a tremendous 
undiscovered potential have still been one of the richest sources of bioactive compounds 
to tackle the growing threat of antibiotic-resistant pathogens. Nevertheless, the 
production level of those important compounds is often quite low, and often undetectable 
using current analytical techniques. To expand the chemical repertoire of nature and to 
increase the titer of the natural products, researchers have developed various strategies, 
such as heterologous expression, co-cultivation of different bacteria, optimization of 
fermentation conditions, discovery of new species, engineering of biosynthetic enzymes, 
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and manipulating regulatory elements. Thus, in my dissertation research, I have exploited 
a few of these strategies. First, I heterologously expressed some of the biosynthetic genes 
from the sch biosynthetic gene cluster, resulted in the production of a novel glycosylated 
angucycline. I was also able to generate another new glycosylated derivative of 
angucycline through gene disruption of tailoring enzymes. In this research, I isolated two 
novel angucycline derivatives and gained new insights into the glycosylation steps in the 
biosynthesis of Sch47554 and Sch47555. Next, I engineered the regulatory elements in 
Streptomyces sp. SCC-2136 through the overexpression and targeted gene disruption 
approaches for enhanced production of pharmaceutically important angucyclines. The 
highest titer of Sch47554 was achieved in Streptomyces sp. SCC-2136/ΔschA4 (27.94 
mg/L), which is significantly higher than the wild type. This work thus provides an initial 
understanding of functional roles of regulatory elements in the biosynthesis of Sch47554 
and Sch47555 and several engineered strains with enhanced production of Sch47554. 
Last, I isolated a carotenoid-producing endophytic bacterium from the leaves of the yew 
tree and optimized the fermentation conditions for an improved yield of zeaxanthin 
diglucoside up to 206 ± 6 mg/L. With the introduction of an additional copy of the Pscrt 
gene cluster through an expression plasmid, the engineered strain Pseudomonas sp. 
102515/pOKF192 produced zeaxanthin diglucoside at 380 ± 12 mg/L, which is 85% 
higher than the parent strain. This strain holds a great potential for the production of 
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CHAPTER I INTRODUCTION 
Background 
A wide variety of compounds from various sources, particularly from 
microorganisms, have been historically used to treat diseases. In particular, natural 
products as a source of medicine have long been attractive due to the huge structural 
diversity and promising biological activities such as antimicrobial, anticancer, antitumor, 
antifungal, antiviral, antiparasitic, antioxidant, antihypertensive properties, and so on 
 
FIG. 1. All small-molecule approved drugs 1981–2014s; n=1211. Major 
categories are as follows: “N”, natural product; “NB”, natural product botanical drug; 
“ND”, derived from a natural product and usually a semisynthetic modification; “S”, 
totally synthetic drug often found by random screening/modification of an existing 
agent; “S*”, made by total synthesis, but the pharmacophore is/was from a natural 




(1,2). For instance, penicillin as an early-discovered antimicrobial agent have saved the 
lives of millions of individuals, indicating the historical importance of natural products 
(3). In the past 30 years, natural products and their derivatives occupy a significant 
market share in pharmaceutical industry (Fig. 1) (4). 
Natural products are derived from various natural sources such as bacteria, fungi, 
animals, and plants. There are successful examples of bioactive molecules from each of 
these natural sources. Actinomycetes, particularly Streptomycetes, have been one of the 
richest sources of biologically active secondary metabolites and have possessed a huge 
potential to produce novel, pharmaceutically useful secondary metabolites with a wide 
variety of biological activities (Fig. 2) (5). However, the deployment of any novel 
antibiotic has been followed by the observance of clinically significant resistance to that 
antibiotic in as short as a few years. The Infectious Disease Society of America predicts 
that 70% of hospital-acquired infections in the United States exhibit resistance to one or 
more antibiotics (6). Yet, there have been no new classes of clinically relevant antibiotics 
discovered in over 40 years (7). This discovery void makes the challenge even more 
severe. In addition, the production titers of many pharmaceutically important compounds 
are often low, and sometimes it is too low to detect the products with current analytical 
techniques (8,9). A well-known example is paclitaxel (Taxol®), which has a total market 
value of over $1 billion per year and is used in the treatment of various cancers. For the 
doses needed to treat a single patient, two to four fully–grown trees (less than 0.5 g 
accumulated Taxol per tree) of Taxus brevifolia have to be sacrificed because of the low 




FIG. 2. Chemical structures of some natural drugs with different biological 
activities. 
Technologies to expand chemical diversity or improve the production yields 
of natural products 
To expand Nature’s chemical repertoire and to increase the titers of known natural 
products, researchers have come up with various solutions: heterologous expression, co-
cultivation, fermentation engineering, isolation of new species and strain engineering (12-
14). In particular, strain engineering can be conducted through both metabolic 
engineering of biosynthetic pathways and engineering regulatory networks of secondary 
metabolites in native strains in which secondary metabolite biosynthesis is tightly 
regulated by global and/or pathway-specific regulatory proteins (8,14-18). In this 
dissertation, I have studied some of these approaches in order to understand natural 
product biosynthesis in bacteria with the purpose of generating novel compounds and 
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enhancing the production of known compounds. I will provide some of the successful 
examples for those strategies. 
Co-cultivation 
In Nature, microbes always co-exist within a complex microbial communities and 
compete with other microorganisms for the limited resources and antagonism. This 
natural characteristic of microorganisms favors various defense mechanisms that mainly 
lead to the production of bioactive secondary metabolites (19). Co-cultivation of two or 
more different microorganisms is to mimic the natural ecological settings in a laboratory 
environment. Many natural products are discovered through co-cultivation strategy (16). 
For instance, co-culture of a marine-derived fungus Libertella sp. and a marine-derived 
bacterium Thalassopia sp. led to the production of novel diterpenoids, libertellenones A-
D (20). The new fungal polyketides, fumicyclines A and B were produced in a mixed 
cultivation of Aspergillus fumigatus and Streptomyces rapamycinicus (21). In another 
example, a known compound, holomycin, was produced from the co-cultivation of S. 
clavuligerus, which does not produce holomycin under normal laboratory condition, with 
methicillin resistant Staphylococcus aureus N315 through exploiting adaptive laboratory 
evolution (22). Therefore, the co-cultivation strategy not only produces known natural 
products with potentially higher yields, but also provides a potential mean to activate 
silent biosynthetic gene clusters for the discovery of new natural products. 
Heterologous expression 
Microbes, particularly Escherichia coli and Saccharomyces cerevisiae, have 
proven to be useful microorganisms for heterologous biosynthesis of medicinally 
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important natural products (15). They have been engineered for the enhanced production 
of natural products as well as the discovery of novel natural products (23). Heterologous 
expression also helps researchers understand and engineer the biosynthetic pathways for 
the generation of derivatives of known natural products, which further diversifies the 
chemical repertoire of Nature (24,25). Artemisinic acid, precursor of antimalarial drug 
artemisinin, has been heterologously produced in yeast with a quiet high titer (25 g/L) 
(26). Another example is the heterologous expression of erythromycin and its derivatives 
in E. coli by reconstituting a complex polyketide pathway (27-29). The heterologous 
expression strategy was also utilized for the activation of silent biosynthetic gene clusters 
from various sources, leading to the production of known or novel natural products in the 
host microorganisms (30). Streptomyces is also used for heterologous expression of 
natural products. For instance, a novel thioviridamide derivative was heterologously 
biosynthesized in S. lividans TK23 (31). Recently, a new diol-containing polyketide, 
lavendiol, was discovered by heterologous expression of a silent biosynthetic gene cluster 
from S. lavendulae FRI-5 in the heterologous host, S. avermitilis SUKA22 (32). All these 
examples suggest that heterologous expression can be utilized for the discovery of new 
compounds through activation of silent biosynthetic gene clusters and enhanced 
production of medicinally important compounds. It can also be used to understand and 
manipulate the biosynthetic pathways for the diversification of the chemical repertoire. 
Metabolic engineering 
Metabolic engineering is the introduction of rational changes in the genetic 
makeup of an organism to alter the metabolic profile or improve biosynthetic capabilities 
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(33). It has attracted an increasing interest as a mean to develop high yield bioprocesses 
and produce novel natural and “unnatural” natural products (14). Recent advances in 
polyketide biosynthesis by the techniques of metabolic engineering and systems biology 
established the foundation for combinatorial biosynthesis. The combinatorial biosynthesis 
approach is based on the understanding of the biosynthetic pathway to regulate, delete, 
add, substitute, and recombine the genes from different sources in a host microorganism. 
It has been used to alter the biosynthetic pathways of many natural products, resulting in 
the formation of many new “unnatural” products with new structures and biological 
activities (34). The insertion of module 2 of rapamycin PKS into the mutable site of 
DEBS1-TE led to the production of two novel tetraketides (35). Since chemical 
modification and/or derivatization of natural products are quite difficult due to structural 
complexity, metabolic engineering techniques such as heterologous expression, gene 
disruption and combinatorial biosynthesis are widely-used techniques and have been 
utilized for the diversification of natural products (14). Mithramycin SK, a novel 
antitumor drug with improved therapeutic index, was produced in the mithramycin 
producer S. argillaceus through combinatorial biosynthesis (36). Another simple 
approach for structural derivatization is the disruption of a particular gene that acts in a 
downstream pathway (usually a tailoring enzyme) (37). A typical example is the 
generation of a macrolide derivative without the epoxide functional group by the targeted 
gene disruption of a P450 epoxidase in the pimaricin gene cluster (38). In addition, 
heterologous co-expression of a set of genes with glycosyltransferases (GTs) in S. 
lividans led to the generation of a new tetracenomycin derivative (39). In this 
dissertation, I have exploited the latter two strategies (gene disruption and heterologous 
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expression) in order to generate novel derivatives and gain new insights into the 
glycosylation steps in the biosynthesis of angucyclines, Sch47554 and Sch47555. 
GTs catalyze the transfer of activated sugar moieties to the acceptor molecules 
and are commonly involved in the biosynthesis and modification of many 
pharmaceutically significant natural products (40). Regio- and stereo-specifically 
attached sugar moieties play important roles in both binding of drugs to biological targets 
and biological activity of many natural products (41,42). For instance, landomycin A 
with a hexasaccharide side chain exhibits much stronger antitumor activity compared to 
its analog, landomycin E with a trisaccharide side chain (43). GTs hold huge potential for 
helping diversify pharmaceutically important drugs through the combination of 
chemoenzymatic and in vivo biosynthetic methods (44). For this purpose, heterologous 
expression and in-frame gene deletion approaches have been implemented in many 
studies. For example, Rodriguez et al. generated hybrid elloramycin analogs by 
combinatorial biosynthesis using genes from anthracycline-type and macrolide 
biosynthetic pathways (45). Tang and McDaniel also benefited from combinatorial 
biosynthesis to produce desosaminylated macrolactones and paved the way for the 
production of ‘unnatural’ natural product libraries (46). Trefzer et al. were able to 
produce novel glycosylated urdamycin derivatives by overexpressing GT genes from 
landomycin-producing strain of S. cyanogenus S136 in a mutant of urdamycin-producing 
strain of S. fradiae Tü 2717 (47). With a similar strategy, Ostash et al. generated novel 
landomycins in a mutant strain (43). Künzel et al. and Luzhetskyy et al. performed 
targeted gene inactivation including the inactivation of genes encoding GTs, leading to 
the formation of urdamycins I, J, K and landomycins M and O, respectively (48,49). All 
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these studies indicate that novel and/or unnatural natural products can be generated by the 
inactivation of GT genes and heterologous expression. 
Strain engineering 
With the recent advances in genome sequencing and recombinant DNA 
technologies, rational strain improvement through metabolic engineering has become a 
powerful tool for increasing titers of natural products. Some of widely-used metabolic 
engineering techniques for yield improvement are to increase the precursor supply, delete 
or tune the competing pathways or unwanted by-products, heterologous expression of the 
entire biosynthetic pathway, overexpression of rate-limiting enzymes and manipulation of 
regulatory genes (14,37). Typically, the best yields are achieved through a combination 
of several approaches. The production of artemisinin precursor, amorphadiene is a very 
successful example of metabolic engineering for yield improvement (15). Keasling and 
co‐workers engineered an artemisinic acid‐producing yeast strain in three steps: (i) 
engineering an farnesyl diphosphate (FPP) biosynthetic pathway to increase FPP 
production and reduce FPP use for sterol biosynthesis, (ii) introducing an amorphadiene 
synthase (ADS) gene from Artemisia annua into an efficient FPP producing yeast, and 
(iii) expressing a novel cytochrome P450 from A. annua (CYP71AV1), oxidizing 
amorphadiene to artemisinic acid in three steps, in an efficient amorphadiene‐producing 
yeast (50). In this study, engineered S. cerevisiae with the ADS gene only produced low 
amounts of amorphadiene (4.4 mg/L). The overexpression of a truncated 3‐hydroxy‐3‐
methyl‐glutaryl‐coenzyme A reductase (tHMGR), which is a rate-limiting step in the 
mevalonate pathway, increased amorphadiene production by five‐fold. They also 
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overexpressed a global transcription factor, UPC2, which regulates sterol biosynthesis in 
yeast, but this approach had a modest impact on amorphadiene production. However, the 
combination of this approach with the down regulation of ERG9 encoding squalene 
synthase, which itself increased amorphadiene production two‐fold, led to the production 
of amorphadiene at 105 mg/L. In addition, they integrated another copy of tHMGR, 
resulting in the production of amorphadiene at 149 mg/L. The combination of all 
aforementioned modifications in the heterologous host led to the production of 153 mg 
amorphadiene/L that is approximately 500‐fold higher than previously reported 
sesquiterpene production (50,51). Moreover, an artemisinic aldehyde ∆11(13) double 
bond reductase (DBR2) was co‐expressed with FPPS, ADS, CYP71AV1 and P450 
reductase, leading to the production of both artemisinic acid and dihydroartemisinic acid 
(52). Additionally, an aldehyde dehydrogenease (ALDH1) and artemisinic alcohol 
dehydrogenase (ADH1) were identified from A. annua. The expression of ALDH1 gene 
in yeast increased artemisinic acid production substantially. The combined heterologous 
expression of ALDH1 and ADH1 in S. cerevisiae with improvements in the fermentation 
process gave the result of the highest artemisinic acid production, 25 g/L (26). In this 
example, heterologous expression of the entire biosynthetic gene cluster, tuning the 
competing pathway and overexpression of bottle-neck enzymes led to a significant 
increase in the yield of amorphadiene. Moreover, manipulation of regulatory genes 
through overexpression of activator genes and/or deletion of repressor genes has been 
successfully performed to improve the yields of natural products (53). For instance, 
overexpression of an Streptomyces antibiotic regulatory protein (SARP) from the 
mithramycin biosynthetic gene cluster in S. argillaceus led to a 16-fold increase in the 
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mithramycin titer (54). Also, inactivation of a GntR family transcriptional repressor 
increased the yield of platensimycin and platencin by 100-fold compared to the wild type 
strain (55). 
Pathway-specific regulatory genes can either activate or repress the expression of 
certain genes in the gene clusters. Bacterial pathway-specific regulators are classified into 
approximately 50 families based on the sequence alignment, structural and functional 
criteria (56). Among the known regulators in Streptomyces, the LuxR family 
transcriptional factors and SARPs are mainly activators as in the examples of GdmRI, 
GdmRII, ActII-orf4 and RedD (57,58). The TetR family transcriptional regulators mainly 
function as repressor as in the examples of TdrK, AlpZ and SAV576 (59-61). However, 
some of the TetR family regulators were characterized as activators, such as GdmRIII, 
SlgR1 and SAV3818 (62-65). Similar to the TetR family regulators, the AraC family 
transcriptional regulators can function as either activator or repressor (66-68). Knowledge 
of the function of regulatory proteins at molecular level is of great interest and would 
potentially increase the yields of secondary metabolites through either inactivation of 
repressors or overexpression of activators and a combinatorial approach of both 
inactivation and overexpression. 
Streptomyces sp. SCC-2136 (ATCC 55186) produces Sch47554 and Sch47555 
that exhibit antifungal activity against various yeasts and dermatophytes (69). In addition, 
Sch47554 and Sch47555 might potentially possess antitumor and antimicrobial activities, 
and enzyme inhibitory and agonistic activities due to their structural similarity to other 
angucycline metabolites (70). The diverse and promising biological activities of 
angucyclines excite the attentions of researcher to study their biosynthesis and to enhance 
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the titer of these pharmaceutically significant compounds. The biosynthetic gene cluster 
(sch) for these angucyclines contains several open reading frames (ORFs) that may 
produce genes with a potential regulatory function. Two putative regulatory genes, schA4 
and schA21, were predicted as the TetR family transcriptional regulators, while schA16 
shared significant similarity to the AraC family transcriptional regulators (71). In this 
dissertation, I have manipulated the pathway-specific regulatory genes in the sch 
biosynthetic gene cluster for an improved yield of angucyclines in Streptomyces sp. SCC-
2136. 
Discovery of new species/strains 
The need for novel drugs for the treatment of human diseases is ever increasing. 
The field of drug discovery has regained the interest due to the rapid development of 
drug-resistant microbes, the discovery of new cases of life-threatening infections and the 
constant recurrence of diseases (72). In addition to aforementioned strategies for the 
production of novel natural products, isolation of new species is another important 
strategy because there is an estimated more than 99 per cent of species left undiscovered 
in the world (73). In particular, endophytes hold a huge potential for the discovery of 
natural products with pharmaceutical importance (74). Endophytes, microorganisms 
(bacteria and fungi) that live in the tissues of living plants without causing any apparent 
disease symptoms in the host, are relatively understudied as potential sources of novel 
natural products for exploitation in medicine, agriculture, and industry (75,76). For 
example, the ecomycins, a family of novel lipopeptides, consist of some unusual amino 
acids including homoserine and β-hydroxy aspartic acid. The endophytic bacterium, 
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Pseudomonas viridiflava produces ecomycins (77). Another example is pseudomycins, 
which represent a group of peptide antifungal compounds isolated from Pseudomonas 
syringae, a plant-associated bacterium (11). New species can sometimes lead to the 
rediscovery of known natural products as happened in the example of camptothecin, a 
potent antineoplastic agent. Camptothecin was originally isolated from the wood of 
Camptotheca acuminate. Interestingly, several endophytes such as Entrophospora 
infrequens and Nodulisporium sp. were reported to produce camptothecin (76), 
representing an alternative and potential mean for the production of this pharmaceutically 
important molecule. In this dissertation, I isolated an endophytic bacterium that produces 
carotenoids, predominantly zeaxanthin diglucoside. 
Fermentation engineering 
One of the main limiting factors for drug discovery is the ability to produce 
sufficient amounts of bioactive molecules for clinical applications after their discovery 
(78) since these compounds are just produced by bacteria to defend their resources and 
territories against invaders and competitors (79). Often, bacteria only need the bioactive 
metabolites to fulfill the purpose of defense and thus do not produce in large amounts 
(80). Fermentation engineering of natural product-producing bacteria is a strong strategy 
to enhance the yield of natural products. Clavulanic acid is a successful example for the 
fermentation engineering to maximize the production. The yield of clavulanic acid was 
enhanced from microgram level (400 μg/L) up to gram level (1.8 g/L) in S. clavuligerus 
through the optimization of fermentation conditions, carbon sources, amino acid 
supplementation and fed-batch fermentation (17). In another study, ribosome engineering 
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and fermentation optimization led to the improved production (40-fold higher) of 
tiancimycin A, a potent anticancer agent, in Streptomyces sp. CB03234 (81). In our lab, 
indigoidine production in E. coli was significantly increased up to approximately 4 g/L 
through optimization of fermentation conditions and co-expression of Sc-IndC and Sc-
IndB (82). These examples clearly indicate fermentation engineering has a huge potential 
to increase the titer of natural products in wild type or engineered microorganisms. In my 
dissertation, I will test to increase the yield of zeaxanthin diglucoside through the 
optimization of fermentation conditions. 
Objectives 
The main goal of my doctoral dissertation research is to engineer bacterial natural 
product biosynthetic pathways for the generation of novel compounds and improved 
production of known medicinally important compounds. Additionally, I isolate 
endophytic bacteria with the purpose of discovering new drugs and providing new means 
to produce known natural products. 
Specific objectives include: 
1- Investigation of glycosylation steps in the biosynthesis of Sch47554 and 
Sch47555  
a) Heterologous expression of minimal PKS enzymes (SchP4-P10) with a 
glycosyltransferase (SchS7) 
b) Targeted gene disruption of SchS9 and SchS10 
2- Engineering regulatory elements in the sch biosynthetic gene cluster for the 
improved production of Sch47554 
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3- Isolation of a carotenoid-producing endophytic bacterium and optimization of 
culture conditions to improve the yield 
A guide to the dissertation 
This dissertation contains five chapters. The first chapter provides a background 
literature review and the objectives of this dissertation. The second chapter is about the 
glycosylation steps in the biosynthesis of antifungal angucyclines with the purpose of 
understanding the pathway and generating novel compounds. Briefly, I heterologously 
expressed some of the biosynthetic genes from the sch biosynthetic gene cluster, which is 
responsible for the biosynthesis of angucyclines in Streptomyces sp. SCC-2136. That led 
to the production of a novel glycosylated derivative of rabelomycin. I was also able to 
generate another new glycosylated derivative of angucycline through metabolic 
engineering of biosynthetic pathways in the wild type strain. In Chapter 3, I engineered 
the regulatory elements in Streptomyces sp. SCC-2136 through overexpression and 
targeted gene disruption approaches. Two engineered strains led to the approximately 4 
times higher yields compared to the wild type strain. Chapter 4 describes the isolation of 
an endophytic bacterium from a tree leaf. This endophytic strain produces carotenoids, 
particularly zeaxanthin diglucoside. This chapter also includes the optimization of the 
fermentation conditions for an improved yield of zeaxanthin diglucoside. The last chapter 
summarizes this dissertation research and its engineering value, and discusses the future 
work. 
A number of research techniques are used in these studies, including molecular 
cloning, genetic engineering, metabolic engineering, microbial fermentation, protein 
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expression, natural products purification, and spectroscopic analyses for structure 
determination, DNA sequence analysis, aseptic techniques, laboratory skills, and others. 
A detailed explanation of each chapter is shown in the following chapters.  
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CHAPTER II NEW INSIGHTS INTO THE GLYCOSYLATION STEPS IN THE 
BIOSYNTHESIS OF SCH47554 AND SCH47555* 
Abstract 
Sch47554 and Sch47555 are antifungal compounds from Streptomyces sp. SCC-
2136. The availability of the biosynthetic gene cluster made it possible to track down the 
genes encoding biosynthetic enzymes responsible for the structural features of these two 
angucyclines. Sugar moieties play important roles in the biological activities of many 
natural products. Investigation of glycosyltransferases (GTs) may potentially help 
diversify pharmaceutically significant drugs through combinatorial biosynthesis. 
Sequence analysis indicated that SchS7 is a putative C-GT, while SchS9 and SchS10 
were proposed to be O-GTs. In this study, we characterized the roles of these three GTs 
in the biosynthesis of Sch47554 and Sch47555. Co-expression of the aglycone and sugar 
biosynthetic genes with schS7 in Streptomyces lividans K4 resulted in the production of 
C-glycosylated rabelomycin, which revealed that SchS7 attaches a D-amicetose moiety to 
the aglycone core structure at the C-9 position. Gene inactivation studies revealed that 
subsequent glycosylation steps take place in a sequential manner in which SchS9 first 
attaches either a L-aculose or L-amicetose moiety to the 4'-OH of the C-glycosylated 
aglycone, then SchS10 transfers a L-aculose moiety to the 3-OH of the angucycline core. 
                                                             
* This chapter has been published as Fidan. F.,# Yan, R.,# Gladstone, G., Zhou, T., Zhu, 
D., Zhan, J.*: New insights into the glycosylation steps in the biosynthesis of Sch47554 




Angucycline antibiotics are a group of biologically active natural products 
synthesized by type II polyketide synthase (PKS) complexes through a sequence of 
reactions (1,2). Angucyclines exhibit diverse biological activities including antiviral (SM 
196 B), antibacterial (marangucycline A, vineomycin A1), antitumor (landomycin A, 
urdamycin A, and marangucycline B) and antifungal properties (Sch47554 (1) and 
Sch47555 (2), Fig. 3) (3-8). Sch47554 and Sch47555 are produced by Streptomyces sp. 
SCC-2136 (ATCC 55186) and exhibit antifungal activity against various yeasts and 
dermatophytes (3). The entire biosynthetic gene cluster for the biosynthesis of Sch47554 
and Sch47555 has been previously reported (9). The availability of their biosynthetic 
gene cluster (NCBI accession number AJ628018) made it possible to track down the 
genes encoding biosynthetic enzymes responsible for the structural features of these two 
angucyclines. The Sch47554 and Sch47555 (sch) biosynthetic gene cluster includes 
enzymes responsible for the biosynthesis of the core polyketide backbone (SchP6-P8) 
and nucleotidyl-activated sugar moieties (SchS1-S6). It additionally encodes some 
tailoring enzymes such as aromatase (SchP4), ketoreductase (SchP5), cyclase (SchP9), 
oxygenase (SchP10), and three putative glycosyltransferases (GTs) (SchS7, SchS9, and 
SchS10) (9). 
GTs catalyze the transfer of activated sugar moieties to the acceptor molecules 
and are commonly involved in the biosynthesis and modification of many 
pharmaceutically significant natural products (10). Regio- and stereo-specifically attached 
sugar moieties play important roles in both binding of drugs to biological targets and 
biological activity of many natural products (11,12). For instance, landomycin A with a 
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hexasaccharide side chain exhibits much stronger antitumor activity compared to its 
derivative, landomycin E with a trisaccharide side chain (13). 
GTs hold huge potential for helping diversify pharmaceutically important drugs 
through the combination of chemoenzymatic and in vivo methods (14). For this purpose, 
heterologous expression and in-frame gene deletion approaches have been implemented 
in many studies. For example, Rodriguez et al. generated hybrid elloramycin analogs by 
combinatorial biosynthesis using genes from anthracycline-type and macrolide 
biosynthetic pathways (15). Tang and McDaniel also benefited from combinatorial 
biosynthesis to produce desosaminylated macrolactones and paved the way for the 
production of ‘unnatural’ natural product libraries (16). Trefzer et al. were able to 
produce novel glycosylated urdamycin derivatives by overexpressing GT genes from 
landomycin-producing strain of S. cyanogenus S136 in a mutant of urdamycin-producing 
strain of S. fradiae Tü 2717 (17). With a similar strategy, Ostash et al. generated novel 
 
FIG. 3. Structures of Sch47554 (1) and Sch47555 (2). 
30 
 
landomycins in a mutant strain (13). Künzel et al. and Luzhetskyy et al. performed 
targeted gene inactivation including the inactivation of genes encoding GTs, leading to 
the formation of urdamycins I, J, K and landomycins M and O, respectively (18,19). All 
these studies indicate that novel and/or unnatural natural products can be generated by the 
inactivation of GT genes and combinatorial biosynthesis. 
In the present study, we elucidated the roles of three GTs involved in the 
biosynthesis of 1 and 2. We have used two aforementioned approaches to functionally 
characterize GTs in the sch biosynthetic gene cluster. The function of schS7 was 
characterized through heterologous expression, while we performed targeted gene 
inactivation for schS9 and schS10. These two approaches not only revealed the function 
of GTs, but also helped to diversify the pharmaceutically relevant molecules through the 
production of two novel compounds. 
RESULTS AND DISCUSSION 
Sequence analysis of the putative GTs in the sch biosynthetic gene cluster 
The sch biosynthetic gene cluster contains three putative GT genes (schS7, schS9, 
and schS10). Multiple amino acid sequence analysis of SchS7 using Clustal Omega 
revealed its homology to known C-GTs: 72.33% identity with UrdGT2 from S. fradiae, 
68.78% identity with SaqGT5 from Micromonospora sp. Tü 6368, and 55.97% identity 
with SimB7 from S. antibioticus Tü6040, as well as to a known O-GT, LanGT2 from S. 
cyanogenus with 58.71% identity (14,20-22). Multiple amino acid sequence analysis of 
SchS9 revealed its similarity to several characterized O-GTs: 58.91% identity with 
UrdGT1c from S. fradiae, 58.21% identity with SaqGT4 from Micromonospora sp. Tü 
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6368, and 54.38% identity with LanGT1 from S. cyanogenus (17,21,23). Similarly, 
multiple amino acid sequence analysis of SchS10 revealed its homology to a few O-GTs: 
54.50% identity with SaqGT2 from Micromonospora sp. Tü6368, 49.40% identity with 
LanGT4 from S. cyanogenus, and 48.82% identity with UrdGT1a from S. fradiae 
(17,21,23). Clustal Omega multiple sequence alignments for each GTs (Figs. B1a-c) 
indicated that SchS7 is expected to possess the function of C-GT, whereas SchS9 and 
SchS10 are predicted as O-GTs. 
Functional characterization of schS7 through heterologous expression 
Based on the sequence analysis, SchS7 is predicted to be responsible for the 
attachment of a sugar moiety to C-9 of the aglycone backbone via the formation of a C-C 
bond. To verify the function of this putative C-GT, we first aimed at the expression of 
minimal PKS genes of sch gene cluster (schP6-P8) and of oxy gene cluster (oxyABC) to 
test the putative functions of SchP6, SchP7, and SchP8, which led to the production of 
SEK15, the same product from the co-expression of OxyABC from the oxytetracycline 
biosynthetic pathway (data not shown) (24). We then expressed more genes in an attempt 
to produce a stable aglycone for GT studies. To this end, schP4-P10 genes were ligated 
into the pRM5 vector, an Escherichia coli/Streptomyces shuttle vector to yield pOF10, 
which was then expressed in S. lividans K4. HPLC analysis revealed that a major product, 
3, was generated by S. lividans K4/pOF10 through heterologous expression of schP4-P10 
genes (pOF10) in S. lividans K4 (Fig. 4A). The ESI-MS spectrum of 3 showed the [M+H]+ 
ion peak at m/z 339.0 (Fig. B2), indicating that its molecular weight is 338, which is same 
as that of rabelomycin, a common intermediate in angucycline biosynthesis. The structure 
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of 3 was confirmed to be rabelomycin (Fig. 4B) based on a comparison of its 1H NMR data 
for 3 with previously reported data (25). 
Using the same approach, we introduced more genes including schS7 and the 
genes involved in the biosynthesis of activated sugar moieties (schS1-S6 and schS8) to 
pOF10 to yield pGG31. Expression of this set of genes in S. lividans K4 yielded another 
major product 4, as shown in Fig. 4A. The ESI-MS spectrum of 4 revealed the [M+H]+ 
ion peak at m/z 453.1 (Fig. B2), suggesting a molecular weight of 452. 4 is 114 mass 
units larger than 3, indicated that 4 is a D-amicetosylated derivative of 3. To elucidate the 
structure of 4, HR-MS analysis was conducted and showed a [M+H]+ ion peak at m/z 
453.1561, which is consistent with C25H25O8 (cacld. 453.1505) (Fig. B6a). The formula 
of 4 revealed that it has 25 carbons, which has 6 more carbons than 3, further indicating 
that a D-amicetose moiety had been added. This was supported by 1D and 2D NMR 
analysis (Table 1, Fig. 5 and Figs. B3a-d). The NMR data of 4 are similar to those of 3, 
except that it has extra signals that belong to the D-amicetose moiety. The 13C NMR 
spectrum showed 25 carbon signals. The chemical shifts of C-6 (δ 152.3) and C-8 (δ 
157.9) indicated that they are hydroxylated carbons on the aromatic rings. Additionally, 
an oxygenated quaternary carbon signal at δ 71.3 was assigned to C-3. These signals are 
consistent with those in rabelomycin. The six carbon signals at δ 73.0, 33.2, 32.0, 79.2, 
71.2 and 18.2, and another hydroxylated CH signal belong to the D-amicetose moiety, 
which further confirmed the presence of this sugar moiety in 4. The HMBC correlation of 
the anomeric proton H-1 at δH 4.79 to C-9 (δC 139.8) confirmed the linkage of the D-
amicetose moiety to the C-9 position (Fig. 5). Accordingly, the structure of 4 can be 
identified as 9-D-amicetosyl-rabelomycin and this compound was named as GG31. 
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Therefore, the function of SchS7 was identified as a C-GT in the biosynthesis of 
Sch47554 and Sch47555 (Fig. 4B). 
 
 
FIG. 4. Production of rabelomycin (3) and 9-D-amicetosyl-rabelomycin (GG31, 
4) in S. lividans K4 through heterologous expression. (A) HPLC analysis (420 nm) of the 
products of S. lividans K4 harboring pRM5 (upper), pOF10 (middle) and pGG31 
(bottom). (B) Biosynthetic pathway of 3 and 4. 











FIG. 5. Selected 1H-1H COSY and HMBC correlations for 4 and 7. 
Targeted gene inactivation of schS9 and schS10 
Sequence analysis of SchS9 and SchS10 suggested that they are responsible for 
O-glycosylations at 3-OH and 4'-OH of 1 and 2. We inactivated both genes through 
homologous recombination to generate mutants lacking corresponding O-GTs (Fig. 6A). 
Apramycin resistant exconjugants were obtained from intergenic conjugation between 
Streptomyces sp. SCC-2136 and E. coli ET12567 respectively harboring pRY9 and 
pRY10. The confirmation of the single crossover events was performed by PCR using 
vector- (RV-M and M13-47) and genome-specific primers (Fig. 6B). As illustrated in 
Figs. 6A and 6B, the 2.2 kb and 2.1 kb PCR products were amplified from Streptomyces 
sp. SCC-2136/ΔschS9 genome, whereas Streptomyces sp. SCC-2136 wild type genome 
did not yield these fragments. Similarly, we amplified the 2.6 kb and 2.8 kb fragments 
from the genome of Streptomyces sp. SCC-2136/ΔschS10, while we did not obtain these 
expected fragments from the genome of wild type strain. Thus, these PCR results 








FIG. 6. Gene disruption of schS9 and schS10 and HPLC traces for the cultures 
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Streptomyces sp. SCC-2136/wild-type, ΔschS9 and ΔschS10. (A) Single crossover 
recombination strategy for disruption of schS9 (i) and schS10 (ii) in Streptomyces sp. 
SCC-2136. (B) PCR confirmation of the Streptomyces sp. SCC-2136/ΔschS9 (i) and 
Streptomyces sp. SCC-2136/ΔschS10 (ii) single crossover mutants. (i) Confirmation of 
the insertion of pRY09 into the genome of Streptomyces sp. SCC-2136. M: 1 kb plus 
DNA ladder; 1: primers sch9-F/M13-47 with the wild type as the template; 2: primers 
sch9-F/M13-47 with the ΔschS9 mutant as the template; 3: primers sch9-R/RV-M PCR 
with the wild type as the template; 4: primers sch9-R/RV-M PCR product with the 
ΔschS9 mutant as the template. (ii) Confirmation of the insertion of pRY10 into the 
genome of Streptomyces sp. SCC-2136. M: 1 kb plus DNA ladder; 1: primers sch10-
F/M13-47 PCR with the wild type as the template; 2: primers sch10-F/M13-47 with the 
ΔschS10 mutant as the template; 3: primers sch10-R/RV-M with the wild type as the 
template; 4: primers sch10-R/RV-M with the ΔschS10 mutant as the template. (C) HPLC 
traces (at 420 nm) for the cultures Streptomyces sp. SCC-2136/wild-type (upper), ΔschS9 
(middle) and ΔschS10 (bottom). 
Upon confirmation of gene inactivation, the positive exconjugants were grown on 
YM plates supplemented with apramycin for product analysis. HPLC analysis of the 
extracts of the cultures of Streptomyces sp. SCC-2136/ΔschS9 and Streptomyces sp. SCC-
2136/ΔschS10 at 420 nm showed two same products (5 and 6) at 19.6 and 26.5 min in 
both extracts. Streptomyces sp. SCC-2136/ΔschS10 produced two additional compounds 
(8 and 7) at 26.1 and 32.5 min (Fig. 6C). The ESI-MS spectra of 5, 6, 7, and 8 showed the 
[M-H]- ion peaks at m/z 373.0, 469.1, 583.1, and 579.1, respectively (Fig. B4), indicating 
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that their molecular weights are 374, 470, 584, and 580, respectively. We purified all 
these compounds for chemical structure elucidation, except 8 due to the low titer. We 
confirmed the chemical structures of 5 and 6 based on the 1H NMR data as listed in 
Table1. We, additionally, ran 1H, 13C, HSQC, and HMBC NMR as well as HR-MS for 
OZK1 (7) (Table 1, Fig. 5 and Figs. B5a-f) to elucidate the chemical structure of this new 
compound. NMR data analysis for 5 and 6 confirmed that the structures of 5 and 6 
matched with the previously reported compounds of urdamycin X and 3'-
deoxyaquayamycin, respectively (3,26). Urdamycin X was reported to be a surprising 
shunt product in Streptomyces fradie/ΔurdQ/R, while 3'-deoxyaquayamycin is a common 
C-glycosylated intermediate compound in angucycline biosynthesis. 
Compounds 7 and 8, on the other hand, are O‐glycosylated intermediate 
compounds. HR-MS data for 7 indicated a [M−H]− ion signal at m/z 583.2559, which was 
consistent with the calculated exact mass of 583.2224 (Fig. B6b); this indicated that the 
molecular formula of 7 was C31H36O11, as supported by the NMR spectroscopic data 
(Table 1), which contained 31 carbon signals. The chemical shift of C‐8 (δ 159.3) 
indicates a hydroxy group attached to the aromatic ring. In addition, similar to 6, 
compound 7 contains tertiary hydroxy groups at the C‐4a (δ 132.1) and C‐12b (δ 133.9) 
positions and an anomeric hydroxy group at the C‐4′ position (δ 72.14). As suggested by 
the molecular weight of 7, we found an additional anomeric proton signal (CH‐1′′) at δC 
98.4 and δH 4.91; this indicates that 7 has one more amicetose sugar moiety. HBMC 
correlation of H‐1′′ to C‐4′ revealed the linkage of the second amicetose moiety to 4′‐OH 
of 6. Thus, compound 7 was characterized as L‐amicetosyl‐3′‐deoxyaquayamycin. All 
signals are assigned according to the 1D and 2D NMR spectroscopic spectra (Table 1). 
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Based on our findings, we proposed the glycosylation steps in the biosynthesis of 1 and 2 
as illustrated in Fig. 7. Glycosylation occurs in a sequential manner, in which SchS7 first 
C‐glycosylates the polyketide aglycone, followed by O‐glycosylation of 3′‐
deoxyaquayamycin by SchS9. Lastly, SchS10 attaches the third sugar moiety to the C‐3 
position, which leads to the production of 1 and 2. 
DISCUSSION  
Many natural products are produced through the assembly of their aglycone core 
structure followed by decoration with sugar moieties. The biological activities of many 
natural products, including medicinally significant antibiotics and anticancer drugs, 
depend on the regio‐ and stereospecifically attached sugar moieties (11,27). Chemical 
synthesis of sugar moieties is excessively difficult to perform and impractical to establish 
on a large scale (14). Thus, GTs are useful alternative tools for chemoenzymatic and in 
vivo approaches to develop glycosylated natural products (27). Many GT genes have 
been isolated from antibiotic‐producing microorganisms and functionally characterized, 
mostly by gene inactivation experiments and in a few cases by heterologous expression. 
Among these GTs are lanGT1, lanGT2, lanGT3, and lanGT4 in the landomycin gene 
cluster (14,17,28,29); urdGT1a, urdGT1b, urdGT1c, and urdGT2 in the urdamycin gene 
cluster (20,23,30,31); saqGT1, saqGT2, saqGT3, saqGT4, saqGT5, and saqGT6 in the 
saquayamycin Z gene cluster (21); mtmGI, mtmGII, mtmGIII, and mtmGIV in the 
mithraycin biosynthetic gene cluster (32,33); oleG1 and oleG2 in the oleandomycin gene 
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1 - - - - - 195.1 174.4 
2 
2.99  
(d, 1H, 15.1) 
3.07  
(d, 1H, 15.2) 
2.80  
(d, 1H, 14.6) 
2.95  
(d, 1H, 14.7) 
1.95  
(dd, 1H, 13.9, 3.0) 
2.33  
(d, 1H, 13.8) 
2.35 (d, 2H, 15.0) 
2.62  
(d, 2H, 14.8) 
53.4 44.8 
3 - - - - - 71.3 72.16 
4 3.12 (s, 2H) 
3.14  
(d, 2H, 11.9) 
2.20 (d, 1H, 10.5) 
2.03  
(dd, 1H, 10.5, 3.3 ) 
2.90 (d, 1H, 13.0) 
3.02 (d, 1H, 13.0) 
3.08  
(dd, 2H, 29.1, 
13.7) 
44.0 41.2 
4a - - - - - 129.7 132.1 
5 7.04 (s, 1H) 7.08 (s, 1H) 
1.67 (m, 1H) 
2.11 (m, 1H) 
7.81 (d, 1H, 7.8) 
7.64  
(d, 1H, 7.7) 
121.5 139.5 
6 - - 
2.61  
(td, 1H, 12.1, 3.4) 
2.85  
(td, 1H, 11.9, 5.6) 
7.72 (d, 1H, 7.7) 
7.82  
(d, 1H, 7.7) 
152.3 119.1 
6a - - - - - 116.8 115.8 
7 - - - - - 193.1 188.3 
7a - - - - - 114.8 115.3 
8 - - - - - 157.9 159.3 
9 
7.30  
(d, 1H, 2.6) 
- 
7.25  
(dd, 1H, 6.3, 2.7) 








(d, 1H, 4.7) 
7.94  
(d, 1H, 7.7) 






(d, 1H, 4.8) 
7.56 
 (d, 1H, 7.6) 
7.58 (d, 1H, 7.6) 7.79 (d, 1H, 6.3) 
7.85  
(d, 1H, 7.9) 
118.2 119.6 
11a - - - - - 138.1 131.5 
12 - - - - - 182.9 188.0 
12a - - - - - 138.2 161.0 
12b - - - - - 128.6 133.9 
13 1.52 (s, 3H) 1.47 (s, 3H) 1.54 (s, 3H) 1.16 (s, 3H) 1.34 (s, 3H) 29.6 27.2 
1' - 
4.79  
(d, 1H, 10.8) 
- 4.70 (d, 1H, 10.6) 
4.85  






1.39 (m, 1H) 
2.09 (m, 1H) 





1.55 (m, 1H) 
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- 3.33 (m, 1H) 3.55 (m, 1H) 71.16 77.6 
6' - 
1.33 
 (d, 3H, 6.0) 
- 1.26 (d, 3H, 6.0) 
1.35 
 (d, 3H, 6.1) 
18.2 18.5 
1'' - - - - 4.91 (s, 1H) - 98.4 
2'' - - - - 1.90 (m, 2H) - 27.7 
3'' - - - - 1.80 (m, 2H) - 30.5 
4'' - - - - 3.31 (m, 1H) - 72.14 
5'' - - - - 3.76 (m, 1H) - 69.9 
6'' - - - - 
1.27  
(d, 3H, 6.2) 
- 17.8 











Compounds 1 and 2 are two antifungal angucyclines that possess three sugar 
moieties. However, how these sugars are added to the structures remains unknown. The 
sch gene cluster contains three putative GT genes (schS7, schS9, schS10) (9). Based on a 
multiple sequence comparison of the deduced amino acid sequences of GTs in the sch 
biosynthetic gene cluster, SchS7 showed high homology to several known C-GTs 
including UrdGT2, SaqGT5, and SimB7. SaqGT5 attaches an activated D-olivose moiety 
directly to the C-9 position of angucycline in the case of saquayamycin Z and of 
tetracenequinone in the case of galtamycin B (21). SimB7 and UrdGT2 are also 
responsible for the attachment of an activated D-olivose to C-9 of polyketide aglycone 
(22,30). In particular, UrdGT2 attaches an activated D-olivose to C-9 of 2-hydro-3-
hydroxy-prejadomycin (UWM6) or terangulol (14,30). The examples of SaqGT5 and 
UrdGT2 show the substrate flexibility that will facilitate the synthesis of derivative 
compounds using those C-GTs. UrdGT2 also functions as O-GT and transfers the 
activated D-olivose sugar moiety to 1,2-dihydroxyanthraquinone (20). Surprisingly, 
multiple sequence comparison also revealed high homology of SchS7 to a known O-GT, 
LanGT2 from S. cyanogenus which catalyzes the first glycosylation step by attaching 
activated D-olivose to 8-OH of the aglycone (14). Interestingly, an engineered version of 
LanGT2 was able to act as C-GT, showing activity for both C- and O-glycosylation 
similar to UrdGT2 (20,37). Therefore, we expected SchS7 to be responsible for the 
attachment of D-amicetose to C-9 of the polyketide aglycone. To characterize its 
function, we have used a heterologous expression approach to create two expression 
plasmids, pOF10 and pGG31. pOF10 contains the minimal PKS genes (schP6, schP7, 




schP5, schP9, and schP10), while pGG31 additionally includes schS7 and genes required 
for the biosynthesis of activated sugar moieties (schS1, schS2, schS3, schS4, schS5, 
schS6, and schS8). S. lividans K4 harboring pOF10 and pGG31 respectively produced 
two major peaks of rabelomycin (3) and a novel compound, 9-D-amicetosyl-rabelomycin 
(4), proving that SchS7 is responsible for the attachment of a D-amicetose sugar moiety 
to the C-9 position of 3. 
Sequence analysis of SchS9 and SchS10 revealed that they are homologous to 
known O-GTs such as UrdGT1a, UrdGT1c, SaqGT2, SaqGT4, LanGT1, and LanGT4. In 
particular, SchS9 is highly homologous to SaqGT4 and UrdGT1c which attach activated 
L-rhodinose to the first sugar moiety in the biosynthesis of saquayamycin Z and 
urdamycin A, respectively. UrdGT1c transfers a L-rhodinose sugar moiety to 
urdamycinone B, 100-2, and aquayamycin at 3'-OH, while SaqGT4 attaches the third and 
fifth sugar moieties at 3-OH of the saccharide chain (21,23). This indicates the substrate 
flexibility of these enzymes and SchS9 might potentially recognize different substrates. 
Additionally, SchS9 has high homology to LanGT1 from the landomycin biosynthetic 
gene cluster that is responsible for the attachment of D-olivose to 4'-OH of the first sugar 
moiety (17). For SchS10, a multiple sequence alignment showed that it is highly 
homologous to SaqGT2 and UrdGT1a that are responsible for the attachment of L-
rhodinose at 12b-OH and 3-OH, respectively (21,23). The amino acid sequence of 
SchS10 is also similar to that of LanGT4 which, in contrast to SaqGT2 and UrdGT1a, 
attaches the third sugar moiety (L-rhodinose) to the saccharide chain at C-9 (17). 
Therefore, both SchS9 and SchS10 are expected to catalyze the O-glycosylation steps in 




corresponding genes through targeted gene deletion. HPLC analysis of the extracts of 
Streptomyces sp. SCC-2136/ΔschS9 and Streptomyces sp. SCC-2136/ΔschS10 mutants 
revealed that both mutants produced 5 and 6 in common. Streptomyces sp. SCC-
2136/ΔschS10 produced two additional compounds (7 and 8) (Fig. 6C). Except 8 which 
was only characterized with LC-MS due to the very low titer, all compounds were 
purified and characterized by LC-MS and NMR. Production of these compounds in the 
mutant strains indicates that O-glycosylation takes place in a sequential manner in which 
SchS9 first attaches either L-amicetose or L-aculose moiety to 4'-OH of 6, then SchS10 
transfers a L-aculose moiety to 3-OH of 7 or 8 to yield 1 and 2 (Fig. 7). SchS9 has 
relatively relaxed substrate specificity toward sugar donors as shown by its ability to 
attach two different sugar moieties, while SchS10 is flexible with sugar acceptors and can 
recognize both 7 and 8 as substrate. Compound 8 might be a more favorable substrate for 
SchS10 than 7 due to a higher titer of 1 compared to 2 in the wild type, whereas more 
efficient production of 7 than 8 in Streptomyces sp. SCC-2136/ΔschS10 mutant indicates 
that SchS9 favorably attaches an activated L-amicetose moiety to 4'-OH of 6. 
Additionally, the presence of 6 in both Streptomyces sp. SCC-2136/ΔschS9 and ΔschS10 
extracts suggests that SchS7 is the dedicated C-GT that catalyzes the first glycosylation 
with 9-deolivosyl aquayamycin as the sugar acceptor substrate. Compounds 3 and 4 were 
not detected in the wild type and mutant strains of Streptomyces sp. SCC-2136. The 
enzymes involved in 6-reduction, 5,6-dehydration, and 12-oxygenation may not 
recognize a glycoside substrate, such as 4. The production of 4 through heterologous 





In addition, both mutant strains produced 5 that was reported as a shunt product. 
Similar to 5, urdamycin L was detected in a ΔurdM mutant of S. fradiae during the 
Baeyer-Villiger monooxygenation process in the biosynthesis of urdamycin A (25). 
Compound 5 is different from urdamycin L due to the almost saturated ring B (additional 
OH groups at C‐4a and C‐12b), whereas urdamycin L possesses a phenolic arene ring B 
with an OH group at C‐6 (Fig. 7) (26). However, both compounds are related to each 
other by an unusual ε‐lactone as ring A. Urdamycin L is derived from the Baeyer-Villiger 
monooxygenation reaction through spontaneous oxidation, whereas 5 is an overoxidized 
analogue of urdamycin L (25,26). In the sch biosynthetic gene cluster, there are 
oxygenases, such as schP3 and schP10, with high homology to urdM (64 %) and urdE 
(84 %), respectively. These enzymes might be responsible for the oxygenation of the 
angucycline ring. It is surprising that 5, as a shunt product, was produced in larger 
quantities than the biosynthetic intermediate 6 in the schS9 and schS10 disruption 
mutants (Fig. 6C). Because schS7 is located downstream of schS9 and schS10, there is a 
possibility that a polar effect occurs if the disruption plasmids are inserted into the 
genome. This polar effect may cause a low‐level expression of C‐GT, SchS7, and thus, 
the overall attenuation of the biosynthetic route of 6. This will in turn lead to the 
increased accumulation of 5. 
CONCLUSION 
We used two different approaches to characterize the functions of three GTs in 
the sch biosynthetic gene cluster; heterologous expression for SchS7 and targeted gene 




analysis of these GTs with their homologues, we found that the glycosylation process in 
the biosynthesis of 1 and 2 occurred in a sequential manner. First, SchS7, which is a C‐
GT, attaches a D‐amicetose moiety to the polyketide aglycone, followed by the 
attachment of the second sugar moiety to 4′‐OH of the first sugar moiety by SchS9. In the 
last step, SchS10 transfers an L‐aculose to C‐3 of the glycosylated polyketide aglycone, 
which leads to the biosynthesis of major products 1 and 2. We isolated two novel 
compounds, 4 and 7, from these two different approaches, respectively, diversifying the 
pharmaceutically relevant compounds. Through elucidating the functions of three GTs, 
we may combine them with other GTs to change the saccharide chain, which possibly 
enhances the antifungal activity, and creates structural diversity in angucyclines. 
EXPERIMENTAL SECTION 
Bacterial strains, media, and culture conditions 
S. lividans K4 strains harboring pOF10 and pGG31 were maintained on R5 agar 
plates supplemented with thiostrepton at 28 °C for 10 days. Streptomyces sp. SCC‐
2136/ΔschS9 and Streptomyces sp. SCC‐2136/ΔschS10 mutants were grown on YM agar 
plates supplemented with apramycin at 28 °C for 10 days. Streptomyces sp. SCC‐2136 
was grown in YM broth for 5 days for genomic DNA extraction. E. coli XL1‐Blue and 
ET12567, which were routinely grown in LB broth at 37 °C, were used for general 
genetic manipulations and intergenic conjugation, respectively. MS and ISP4 media were 
used for conjugation and single crossover homologous recombination, respectively. 
Apramycin (50 μg/mL), thiostrepton (50 μg/mL), chloramphenicol (25 μg/mL), 




General genetic manipulation and PCR 
Standard molecular biology protocols were performed as previously described 
(38). Genomic DNA samples of Streptomyces sp. SCC‐2136 and its mutants were 
extracted using a ZR Fungal/Bacterial DNA Miniprep Kit (Irvine, CA, USA). Plasmid 
DNA extraction from E. coli cells was performed using a Thermo Scientific GeneJET 
Plasmid Miniprep Kit (Logan, UT, USA). PCR reactions were performed with an Arktik 
Thermal Cycler (Thermo Scientific) using Phusion DNA polymerase (Thermo 
Scientific). Oligonucleotide primers were ordered from Sigma–Aldrich and dissolved in 
TE buffer to a concentration of 100 ng/mL. 
Construction of plasmids for heterologous expression and gene disruption 
For the heterologous expression approach, schP4, schP5, schP6, schP7, schP8, 
schP9, and schP10 genes were PCR‐amplified from Streptomyces sp. SCC‐2136 genomic 
DNA using the oligonucleotide primers listed in Table B1. Specific forward and reverse 
primers contained compatible restriction enzymes, such as XbaI, SpeI, and NheI. The 
PCR products were first ligated into the pJET1.2 cloning vector for DNA sequencing 
using Sanger’s method (Eton Bioscience, San Diego, CA, USA). Each combination of 
genes was then constructed by the subsequent addition of individual genes into the 
cloning vector and correct ligation was confirmed by restriction enzyme digestions. 
Additionally, each group of genes was ligated into a pRM5‐derived vector. The gene 
cassette containing schP6, schP7, and schP8 was excised from pOF1 using PacI and 
NheI and ligated into pRM5 between the same sites to yield pOF3. Subsequently, the 




the same sites to yield pOF4. schP4, schP9, and schP10 were also excised from pOF5-7 
and inserted in the same sequential manner to yield pOF8‐10, respectively. Similarly, 
schS1, schS2, schS3, schS4, schS5, schS6, schS7, and schS8 were PCR‐amplified from 
the genomic DNA of Streptomyces sp. SCC‐2136 and subsequently inserted into pJET1.2 
to yield pKN57. The gene cassette containing these genes was excised from pKN57 using 
the NheI and SpeI restriction sites, and ligated into pOF10 digested with the same 
restriction enzymes to yield pGG31. pOF10 and pGG31 plasmids were introduced into S. 
lividans K4 through poly(ethylene glycol) (PEG)‐mediated protoplast transformation for 
product analysis. 
For the targeted gene disruption approach, a 672 bp fragment of schS9 and a 763 
bp fragment of schS10 were PCR‐amplified from the genomic DNA of Streptomyces sp. 
SCC‐2136 using the primers listed in Table B1. The PCR products for schS9 and schS10 
were first ligated into the pJET1.2 cloning vector by using T4 DNA ligase (New England 
Biolabs) to yield pRY7 and pRY8, respectively. These plasmids were sequenced to 
ensure that the genes were correct and free of mutations. The inserts were excised from 
pRY7 and pRY8 with XbaI and HindIII (New England Biolabs) and ligated to the 
thermally sensitive plasmid pKC1139 between the same sites to yield pRY9 and pRY10, 
respectively, which were subsequently used for gene inactivation of schS9 and schS10 in 
Streptomyces sp. SCC‐2136 through intergenic conjugation with E. coli ET12567. 
Positive exconjugants for Streptomyces sp. SCC‐2136/ΔschS9 and ΔschS10 mutants were 
transferred to ISP4 plates supplemented with apramycin and nalidixic acid, and incubated 
at 37 °C for about 10 days to allow the plasmids to integrate into the genome and yield 




and ISP4 plates supplemented with apramycin for two generations to guarantee the 
positive mutants. Positive exconjugants after genome integration were subjected to 
product analysis and PCR confirmation of gene knockouts using primers listed in Table 
B1. The details of PEG‐mediated protoplast transformation and intergenic conjugation 
protocols are described in the literature (39). 
Production, extraction, purification, and characterization of compounds 
S. lividans K4, harboring pOF10 and pGG31, and Streptomyces sp. SCC‐
2136/ΔschS9 and Streptomyces sp. SCC‐2136/ΔschS10 mutants were grown for 10 days 
at 28 °C on R5 and YM agar plates supplemented with appropriate antibiotics, 
respectively. The cultures were chopped and extracted with a mixture of solvent 
consisting of 89 % ethyl acetate, 10 % methanol, and 1 % acetic acid (v/v). The resulting 
extracts were dried in vacuo, and the residues were redissolved in methanol for LC‐MS 
analysis. All crude extracts were separated on a silica gel 60 column using different ratios 
of chloroform–methanol. The fractions with target compounds were further separated by 
HPLC with an Agilent Eclipse XDB‐C18 column (5 μm, 250×4.6 mm). Low‐resolution 
ESI‐MS spectra were obtained on an Agilent 6130 LC‐MS. A Waters GCT high‐
resolution mass spectrometer, with EI/CI and LIFDI capabilities (University of 
California, Riverside), was used to obtain the accurate mass spectra for the new 
compounds. 1D and 2D NMR spectra were recorded on a JEOL ECX‐300 or a Bruker 
Avance III HD Ascend‐500 NMR spectrometer. 
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 CHAPTER III IMPROVED PRODUCTION OF ANTIFUNGAL ANGUCYCLINE 
SCH47554 BY MANIPULATING THREE REGULATORY GENES IN 
STREPTOMYCES SP. SCC-2136† 
Abstract 
Sch47554 and Sch47555 are two angucyclines from Streptomyces sp. SCC-2136 
with antifungal activities against various yeasts and dermatophytes. The sch gene cluster 
contains several putative regulatory genes. Both schA4 and schA21 were predicted as the 
TetR family transcriptional regulators, while schA16 shared significant similarity to the 
AraC family transcriptional regulators. Although Sch47554 is the major product of 
Streptomyces sp. SCC-2136, its titer is only 6.72 mg/L. This work aimed to increase the 
production of this promising antifungal compound by investigating and manipulating the 
regulatory genes in the Sch47554 biosynthetic pathway. Disruption of schA4 and schA16 
led to a significant increase in the production of Sch47554, whereas the titer was 
dramatically decreased when schA21 was disrupted. Overexpression of these genes gave 
opposite results. The highest titer of Sch47554 was achieved in Streptomyces sp. SCC-
2136/ΔschA4 (27.94 mg/L), which is significantly higher than the wild type. Our results 
indicate that SchA4 and SchA16 are repressors, while SchA21 acts as an activator. This 
work thus provides an initial understanding of functional roles of regulatory elements in 
the biosynthesis of Sch47554. Several efficient producing strains of Sch47554 were 
                                                             
† This chapter has been published as Fidan. F., Yan, R., Zhu, D., Zhan, J.*: Improved 
production of antifungal angucycline Sch47554 by manipulating three regulatory genes in 





constructed by disrupting or overexpressing particular regulatory genes, which can be 
further engineered for industrial production of this medicinally important molecule. 
INTRODUCTION 
Gram-positive, filamentous, soil-inhabiting bacteria of Streptomyces belong to the 
phylum of Actinobacteria and have been recognized as one of the richest sources of 
biologically active secondary metabolites. They have a complex life cycle of 
morphological differentiation, which begins with spore germination in order to form 
branched vegetative hyphae (1). The subsequent differentiation results in the formation of 
sporogenic aerial hyphae, followed by the chains of unigenomic spores (2). During the 
initiation of morphological differentiation, most of the Streptomyces strains produce an 
extraordinary diversity of bioactive secondary metabolites, including a wide variety of 
pharmaceutically important natural products with various biological activities such as 
antimicrobial, anticancer, antifungal, antiviral and anti-cholesterol properties (3-6). The 
morphological differentiation and secondary metabolite production are tightly controlled 
by a complex network of regulators that senses and responds to plenty of physiological 
and environmental stimuli, including environmental stress, nutrition depletion, growth 
rate and small signaling molecules such as γ-butyrolactone and ppGpp (7-10). The 
regulators function at several hierarchical levels, starting from the highest level of 
regulation (also known as global or pleiotropic regulators), which involves pleiotropic 
genes that play significant roles in morphological differentiation as well as secondary 
metabolite production. The lowest level of regulation utilizes pathway-specific regulatory 




biosynthesis of corresponding secondary metabolites (8,9,11,12). 
Pathway-specific regulatory genes can either activate or repress the expression of 
certain genes in the gene clusters. Biosynthetic gene clusters might have different 
numbers of pathway-specific regulatory genes. For instance, there is one in the 
actinorhodin biosynthetic gene cluster (13), whereas the daunorubicin gene cluster has 
three regulators (14). Some gene clusters, such as that for tylosin biosynthesis (15), 
contain both activators and repressors in the same gene cluster. Bacterial pathway-
specific regulators are classified into approximately 50 families based on the sequence 
alignment, structural and functional criteria (11). Among the known regulators in 
Streptomyces, the LuxR family transcriptional factors and Streptomyces antibiotic 
regulatory proteins (SARPs) are mainly activators as in the examples of GdmRI, 
GdmRII, ActII-orf4 and RedD (13,16). The TetR family transcriptional regulators often 
have the repression function as in the examples of TdrK, AlpZ and SAV576 (17-19). 
However, some of the TetR family regulators were characterized as activators, such as 
GdmRIII, SlgR1 and SAV3818 (20-23). Similar to the TetR family regulators, the AraC 
family transcriptional regulators can also function as either activator or repressor (24-26). 
Knowledge of the function of regulatory proteins at molecular level is of great interest. It 
would potentially enhance the yield of secondary metabolites through either inactivation 
of repressors or overexpression of activators and a combinatorial approach of both 
inactivation and overexpression. 
Streptomyces sp. SCC-2136 (ATCC 55186) produces Sch47554 and Sch47555 
that exhibit antifungal activity against various yeasts (Candida albicans, C. tropicalis and 




tonsurans and Microsporum canis) (27). In addition to reported antifungal activities, 
Sch47554 and Sch47555 (Fig. 3) might potentially possess antitumor and antimicrobial 
activities, as well as enzyme inhibitory and agonistic activities due to their structural 
similarity to other angucycline metabolites (28). The diverse and promising biological 
activities of angucyclines excite the attentions of researcher to study the biosynthesis of 
these pharmaceutically important natural products as well as to enhance the production of 
these compounds. 
The initial sequence analysis of the biosynthetic gene cluster (sch) for Sch47554 
and Sch47555 revealed a total of 55 open reading frames (ORFs) in a region of 77.5 kb 
(NCBI accession number AJ628018). In our previous work, we proposed the biosynthetic 
pathway in which minimal PKS enzymes (SchP6, SchP7, and SchP8) can synthesize 
SEK15 from acetyl-CoA and nine units of malonyl-CoA. The addition of ketoreductase 
(SchP5), aromatase (SchP4) and cyclase (SchP9) to the mimimal PKS produced UWM6, 
which was subsequently converted to rabelomycin by an oxygenase (SchP10). Upon 
another oxygenation step by SchP3, the aglycone backbone was synthesized and further 
modified by three glycosyltransferases, resulting in the biosynthesis of Sch47554 and 
Sch47555 (29,30). Additionally, based on the sequence similarity analysis, the sch gene 
cluster contains several ORFs that may produce genes with a potential regulatory 
function. Two putative regulatory genes, schA4 and schA21, were annotated as the TetR 
family transcriptional regulators, while schA16 shared significant similarity to the AraC 
family transcriptional regulators. In addition to the well-known families of regulatory 
genes, Basnet et al. predicted the putative functions of schA25 and schA27 as repressor-




With the recent advances in genome sequencing and recombinant DNA 
technologies, rational strain improvement through metabolic engineering and synthetic 
biology has become a powerful tool to increase the titers of natural products for industrial 
purposes. Some of widely-used metabolic engineering techniques for yield improvement 
are to increase the precursor supply, delete or tune the competing pathways or unwanted 
by-products, heterologous expression of the entire biosynthetic pathway, overexpression 
of rate-limiting enzymes, and manipulation of regulatory genes (31,32). Typically, the 
best yields are achieved through a combination of several approaches. Moreover, the 
manipulation of regulatory genes through overexpression of activator genes and/or 
deletion of repressor genes has been successfully performed in order for the improved 
yield of natural products (33). For instance, overexpression of a SARP from the 
mithramycin biosynthetic gene cluster in S. argillaceus led to a 16-fold increase in the 
mithramycin titer (34). In addition, the inactivation of a GntR family transcriptional 
repressor increased the yield of platensimycin and platencin by 100-fold compared to the 
wild type strain (35). The aim of the present study was to identify the functional roles of 
the TetR and AraC family transcriptional regulators in the sch gene cluster in 
Streptomyces sp. SCC-2136 for the improved production of the major antifungal 
compound Sch47554. The results presented in this study indicate that SchA4 and SchA16 
are repressors, while SchA21 is an activator based on the inactivation and overexpression 
of corresponding regulatory genes. Manipulation of these regulatory genes significantly 
increased the production of Sch47554. This study paves the way for further engineering 





MATERIALS AND METHODS 
Plasmids, strains, media and growth conditions 
Plasmids and bacterial strains used in this study are listed in Table 2. 
Streptomyces sp. SCC-2136 was used as the parent strain for gene disruption and 
overexpression of regulatory proteins. Streptomyces sp. SCC-2136 was grown in YM 
broth (4 g/L yeast extract, 10 g/L malt extract, 4 g/L glucose) for 5 days for genomic 
DNA extraction. Streptomyces sp. SCC-2136 and its derivative strains were grown at 28 
°C for 10 days on YM agar plates (4 g/L yeast extract, 10 g/L malt extract, 4 g/L glucose, 
and 20 g/L agar) for product analysis. MS (20 g/L mannitol, 20 g/L soy flour, 20 g/L agar 
and 10 mM MgCl2) and ISP4 (Difco
TM) media were used for conjugation and single 
crossover homologous recombination, respectively. Escherichia coli XL1-Blue was used 
as the cloning host for plasmid construction and amplification. E. coli ET12567 was used 
for the introduction of gene knockout and overexpression plasmids into Streptomyces sp. 
SCC-2136 through intergenic conjugation. E. coli strains were routinely grown in LB 
medium at 37 °C. Apramycin (50 μg/mL), kanamycin (50 μg/mL), chloramphenicol (25 
μg/mL), ampicillin (50 μg/mL) and nalidixic acid (25 μg/mL) were supplemented when 
appropriate. 
Standard molecular biology protocols were performed as previously described 
(38). Genomic DNA samples of Streptomyces sp. SCC-2136 and its derivative strains 
were extracted with a ZR Fungal/Bacterial DNA Miniprep Kit (Irvine, CA, USA). 
Plasmid DNA extraction from E. coli cells was performed using the Thermo Scientific 




an Arktik™ Thermal Cycler (Thermo Scientific) using Phusion DNA polymerase 
(Thermo Scientific). Oligonucleotide primers were ordered from Sigma-Aldrich and 
dissolved in TE buffer to the concentration of 100 ng/mL. Restriction enzymes used in 
this study were purchased from New England BioLabs. 
TABLE 2 Bacterial strains and plasmids used in Chapter 3. 
Strains Description Source 
E. coli XL1-Blue 
recA1 endA1 gyrA96 thi-
1 hsdR17 supE44 relA1 lac 
Agilent 
Technologies 
E. coli ET12567 (pUZ8002) 
F- dam-13::Tn9 dcm-6 hsdM hsdR zjj-
202::Tn10 recF143 galK2 galT22 ara-
14 lacY1 xyl-5 leuB6 thi-1 tonA31 
rpsL136 hisG4 tsx-78 mtl-1 glnV44 
(30) 
Streptomyces sp. SCC-2136/WT 






























Streptomyces sp. SCC-2136 schA21 
overexpression strain 
This study 
Plasmids Description Source 




E.coli-Streptomyces shuttle plasmid 





sensitive origin of replication 
pSET152 
















Partial fragment of schA4 gene (from 
pRY15) in pKC1139 
This study 
pRY20 
Partial fragment of schA16 gene (from 
pRY16) in pKC1139 
This study 
pRY21 
Partial fragment of schA21 gene (from 
pRY17) in pKC1139 
This study 
pOKF7 schA4 gene in pJET1.2 This study 
pOKF8 schA16 gene in pJET1.2 This study 
pOKF9 schA21 gene in pJET1.2 This study 
pOKF10 












Plasmid construction for targeted gene disruption and overexpression of 
regulatory genes 
Targeted gene disruption plasmids were constructed based on the temperature-
sensitive vector pKC1139 (36). Firstly, we PCR-amplified 456 bp, 538 bp, and 508 bp 




Streptomyces sp. SCC-2136 using the primers listed in Table 3. These PCR products 
were ligated into the pJET1.2 cloning vector to yield pRY15, pRY16 and pRY17 (Table 
2), respectively. The plasmids were sent out for DNA sequencing using Sanger’s method 
(Eton Bioscience). Subsequently, the partial DNA fragments of schA4, schA16, and 
schA21 genes were excised from pRY15, pRY16 and pRY17 using XbaI and HindIII, 
and then ligated into pKC1139 between the same sites to yield pRY19, pRY20 and 
pRY21 (Table 2), respectively. These plasmids were subsequently used for targeted gene 
disruption of schA4, schA16 and schA21 in Streptomyces sp. SCC-2136 through 
intergenic conjugation using E. coli ET12567. Positive exconjugants for Streptomyces sp. 
SCC-2136/ΔschA4, ΔschA16 and ΔschA21 mutants were transferred to ISP4 plates 
supplemented with apramycin and incubated at 37 °C for about 10 days to allow the 
plasmids to integrate into the genome and yield the single-crossover mutants. The 
positive mutants were shuttled back and forth to YM and ISP4 plates supplemented with 
apramycin for two generations to guarantee the positive mutants. Positive exconjugants 
after genome integration were subjected to product analysis and PCR confirmation of 
gene knockouts using primers listed in Table 3. The details of intergenic conjugation 
protocols were described in the literature (39). 
For overexpression of regulatory genes, an integrative expression plasmid for 
Streptomyces, pSET152, was used (37). We firstly amplified schA4, schA16 and schA21 
genes by PCR from the genomic DNA of Streptomyces sp. SCC-2136 using the primers 
listed in Table 3. These PCR products were inserted into pJET1.2 cloning vector to yield 
pOKF7, pOKF8 and pOKF9 (Table 2), respectively. After sequencing, each regulatory 




into pSET152 using the same site, yielding pOKF10, pOKF11 and pOKF12 (Table 2), 
respectively. The direction of the genes was double-checked using the NdeI restriction 
site, which was designed in the primers for direction check. These plasmids were 
transformed into Streptomyces sp. SCC-2136 through intergenic conjugation using E. coli 
ET12567. Positive exconjugants were streaked on YM plates supplemented with 
apramycin for product analysis. 








OE-schA4-F-XbaI-NdeI  aaTCTAGAgggagccCATATGtcagtccgccgagcggtcc 
OE-schA4-R-XbaI   aaTCTAGAatgaccagcgtcgaagaaccgg 
OE-schA16-F-XbaI-NdeI aaTCTAGAggaggagccCATATGgcggacataagcaccca 
OE-schA16-R-XbaI aaTCTAGAtcagccctgaacgccgccgg 
OE-schA21-F-XbaI-NdeI  aaTCTAGAgggagccCATATGtcagtccgccgagcggtcc 
OE-schA21-R-XbaI   aaTCTAGAatggccactcggagaaaagaggagaagc 
SchA4-RY19-check-F  aaatgacgtagccgacgacg 
SchA4-RY19-check-R  aagtgacatcggtgttgtgc 
SchA16-RY20-check-F  aacagacggtgtggtcgaag 
SchA16-RY20-check-R  aaagaccacgaccgactctg 
SchA21-RY21-check-F  aagtgagccagtcgcagtgc  





Extraction, purification and product analysis 
Streptomyces sp. SCC-2136 and engineered strains were grown for 10 days at 28 
ºC on YM agar plates supplemented with apramycin. The plates were chopped and 
extracted with a mixture of solvents consisting of 89% ethyl acetate, 10% methanol, and 
1% acetic acid (v/v). The resulting extracts were dried in vacuo, and the residues were 
redissolved in methanol for HPLC analysis. We purified the major compound Sch47554 
by HPLC with an Agilent Eclipse XDB-C18 column (5 μm, 250 mm × 4.6 mm) to 
prepare a standard curve for the product analysis of engineered strains. This purified 
compound was characterized by LC-MS and NMR (Figs. C1 and C2). Low-resolution 
and high-resolution ESI-MS spectra were obtained on Agilent 6130 and 6210 LC-MS, 
respectively. Proton NMR was recorded on a Bruker AvanceIII HD Ascend-500 NMR 
instrument.  
1H NMR (500 MHz, CDCl3): δ 7.91 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 
6.94 (d, J = 9.8 Hz, 1H), 6.85 (dd, J = 10.2, 3.5 Hz, 1H), 6.71 (dd, J = 10.2, 3.5 Hz, 1H), 
6.43 (d, J = 9.8 Hz, 1H), 6.13 (d, J = 10.2 Hz, 1H), 6.10 (d, J = 10.2 Hz, 1H), 5.61 (d, J = 
3.4 Hz, 1H), 5.35 (d, J = 3.5 Hz, 1H), 4.83 (d, J = 10.0 Hz, 1H), 4.76 (q, J = 6.7 Hz, 1H), 
4.62 (q, J = 6.8 Hz, 1H), 3.58 (dd, J = 9.1, 6.1 Hz, 1H), 3.43 (ddd, J = 14.5, 10.1, 4.8 Hz, 
2H), 3.25 (dd, J = 13.4, 3.0 Hz, 1H), 2.56 (d, J = 13.3 Hz, 1H), 2.49 (dd, J = 15.6, 2.9 Hz, 
1H), 2.40 – 2.31 (m, 2H), 2.30 – 2.24 (m, 1H), 1.90 – 1.85 (m, 1H), 1.83 (d, J = 15.5 Hz, 
1H), 1.49 (s, 3H), 1.46 (d, J = 6.7 Hz, 3H), 1.41 (d, J = 6.8 Hz, 3H), 1.39 (d, J = 6.1 Hz, 
3H).  
The titers of Sch47554 for all strains were calculated using the standard curve 




formation for all strains. Depending on the production level, the crude extracts of all 
strains were diluted with different ratios in order to be in the range of the standard curve 
and then analyzed by HPLC. 
RESULTS AND DISCUSSION 
Actinomycetes have possessed a huge potential to produce novel, 
pharmaceutically useful secondary metabolites with a wide variety of biological activities 
(40). Particularly, Streptomycetes have been recognized as one of the richest sources of 
biologically active secondary metabolites (41). However, the production titers of those 
important compounds are often low, and sometimes it is too low to detect the products 
with current analytical techniques (42,43). To expand Nature's chemical repertoire and to 
increase the titers of known natural products, researchers have come up with various 
solutions: heterologous expression, co-cultivation, fermentation engineering and strain 
engineering (8). In particular, strain engineering can be conducted through both 
metabolic engineering of rate-limiting and/or competing pathways, and engineering 
regulatory networks of secondary metabolites in native strains in which secondary 
metabolite biosynthesis is tightly regulated by global and/or pathway-specific regulatory 
proteins (40,42,44-47). In this study, we investigated the roles of three regulatory genes 
in the sch biosynthetic gene cluster with the purpose of enhancing the production of 
Sch47554 in Streptomyces sp. SCC-2136. 
Sequence analysis of three putative regulatory proteins in the sch 
biosynthetic gene cluster 




transcriptional factors, while SchA16 is a putative AraC family transcriptional factor. 
SchA4 and SchA21 exhibit high sequence homology to LanK (72% and 76%, 
respectively) and SimR (80% and 63%, respectively), both of which are regulatory 
proteins in the biosynthetic gene clusters of landomycin A and simocyclinone (48-50). 
SchA16 is highly similar to some of the characterized AraC family transcriptional factors 
such as AdpA (78%), RapG (72%), NanR4 (75%) and SAV742 (78%) (24-26,51). We 
also performed a multiple amino acid sequence alignment for those regulatory genes 
against some of the characterized regulatory proteins from various Streptomyces strains 
in order to identify the conserved domains (Fig. 8). The overall conserved structure of the 
TetR family transcriptional factors consists of nine α helices, and the DNA-binding 
domain is composed of helices 1 to 3 (52). Both SchA4 and SchA21 consist of conserved 
DNA-binding domains similar to other reference TetR family transcriptional factors 
(Figs. 8A and 8B). On the other hand, the AraC family transcriptional factors (Fig. 8C) 
possess a C-terminal conserved helix-turn-helix (HTH) DNA-binding domain with the 
consensus of 15 amino acid residues (AxxxxxSxxxLxxxFxxxxGxxxxxxxxxxxRxxx 
AxxxLxxxxxxxxxI/VxI/VxxxxG(F/K)xxxxxxFxxxF(R/K)xxxxGxP, where x is any 
amino acid) (53). SchA16 has high similarity to this consensus sequence. All in all, 
BLAST and Clustal Omega multiple sequence alignments for these regulatory proteins 
indicated that SchA4 and SchA16 belong to the TetR family, while SchA16 is a member 







A                         α1               α2         α3         α4 
 
SAV_151_213aa     -TRLIQAGLDLFGTAGYASASVKQVCSHAGLTERYFYESFRDREDLLAGVY- 
TcmR_226aa        -DQLIREALELFLAQGYEHTTVEQIAEAVEVHPRTFFRHFASKEEVALTPI- 
SCO3201_236aa     -MEIARAAARLFVGQGLRATRAEDIARAAGVAPRTFYRYFATKEEAVAPLY- 
TrdK_214aa        -ETISDTAITLFLEHGFDQVSVVDIAAVAEVSKPTLFKYFPTKEDLVVHRF- 
SchA4_221aa       -AEILDVATHEFARAGYDGARVDEIAARTRTTKRMIYYYFGGKDQLFTAVL- 
RapY_204aa        -EAITEAAFAELADAGYARMSMESVARRAGVGKAALYRRWPSKQAMVTELI- 
ClmR1_185aa       ----MDAAEGVFAERGIDAARIDEITERAGVAIGTFYLHFSSKRDIMAAVQ- 
LanK_192aa        -DKIQSVALELFIERGYEKTSMREIAEGLGITKAALYYHFKAKEEILVAIS- 
Au1R_205aa        -RALIESAARVFGRRGYAEATLSMISVGAGVSPGALHFHFENKAAVAAAVE- 
AlpW_230aa        -EALIRSAAEVFHHEGFTAASLTLISSRAGVSNGALHFHFASKAVLADAVE- 
AlpZ_237aa        -LSILKAAAEVFDSHGYEAATIGEILRRAGVTKGALYFHFPSKQALAEGVL- 
ArpA_276aa        -RSIVDAAASVFDDYGYERAAISEILRRAKVTKGALYFHFASKEAIAQAIM- 
SAV_576_218aa     -DGICAMALQLIDADGVEALTMRKLATALDANPMSLYHHVPNKDAVLRGVA- 
SimR_267aa        -DQIVRAAVKVADTEGVEAASMRRVAAELGAGTMSLYYYVPTKEDLVELMV- 
SACE_0012_229aa   -LRLLDRAGELLAEGGADALGLRSLAKAADTSTSAVYSLFGGKDELLHALY- 
SCO1712_205aa     -TRILDACADLLDEVGYDALSTRAVALRADVPIGSVYRFFGNKRQMADALA- 
TetR_226aa        -NTVIRAALDLLNEVGVDGLTTRKLAERLGVQQPALYWHFRNKRALLDALA- 
                                 *        :          ..     :                                  
B                        α1               α2         α3         α4 
 
SgAtrA_267aa     -EHVLRAAREVFGELGYG-APMEDVARRARVGVGTVYRRFPSKDVLVRRIAE- 
SrAtrA_284aa     -EHVLRAAREVFGELGYG-APMEDVARRARVGVGTVYRRFPSKDVLVRRIAE- 
SlgR1_220aa      -QAISDAAISLFLQHGFDQVSVVDVAAAAEVSKPTLFKYFPTKEDLVVHRFA- 
GouR_228aa       -RALATAALDLILRRGLADTTVEAIAERADVTRRTFSRHFAGKEDAALDFVR- 
SchA21_251aa     -QRIAAAAVAIADTEGLDAVTMRRLAADLGAAPMAAYRYVSGKDELLELMVD- 
GdmRIII_208aa    -VRLLDATVELIGEHGYEATTLADIADRAGAARGLVSYYFPGKRQLLQTAVH- 
SACE_7301_219aa  -RQILDAAVDVFAAHGFHQASMDEISEVAGISKPMIYAYLGSKEELFVACIQ- 
SSDG_03033_207aa -ETLLTVAVQIFNERGYDGTSMEHLSKAAGISKSSIYHHVAGKEELLRRAVS- 
DepR1_210aa      -RAIHDAALALVTEVGYRRTTIEGIAARAGVGKQTIYRWWPSKAAVLIDAFL- 
                    :  .:  :    *   . :  ::                *           
C 
AdpA_405aa        --EHLHEQFDVETLAARAYMSRRTFDRRFR-SLTGSAPLQWLITQRVLQAQR 
NanR4_313aa       ---NPGHPWTVALLAAETGISRAVLARRFT-ELVGEPPMAYLTGWRLDLAAD 
SchA16_297aa      -EKGFATNHSVSAYADALGYSRRTLVRAVR-AATGETPKGFIDKRVVLEAKR 
RapG_330aa        ----TDPELSPTMLARELNVSLRTLQRAFT--VAGESLIAYIRHRRLEEARR 
SAV_742_331aa     ----HDPELSPPVIAAAHHISLSYLHRIFQQQAQGETVAAYIRSQRLEGACR 
                  .             *     *   : * .     *.    ::    :  *   
 
AdpA_405aa        LLETSD---YSVDEVAGRCGFRSPVALRGHFRRQLGSSPAAYRAAYRARR-- 
NanR4_313aa       LLREPD---ATLGAVARRVGYGSSFALSAAFKRVRGVSPREHRSAAS----- 
SchA16_297aa      LLAHTD---MPIGRIGVSVGFPDAANFTKFFHQHTGVAAGGVQG-------- 
RapG_330aa        ALIASA-GRLSVSELAAHWQFADSSHFIRVFKKTYGQTPTEYARSTGLT--- 
SAV_742_331aa     DLASTSLRTTPIYAVAARWGFLHASDFTRTFRTAYGRSPKEYRLQALYV--- 
                   *         :  :.    :     :   *:   * :                




Characterization of SchA4 as a repressor and enhanced production of 
Sch47554 by disrupting schA4 
Based on the multiple amino acid sequence alignment and analysis of the 
conserved domains, SchA4 was predicted to be a TetR family transcriptional factor. To 
characterize the role of schA4, we first disrupted this gene on the genome of 
Streptomyces sp. SCC-2136. A single crossover approach was used (Fig. 9A). Apramycin 
SchA16 (C) with respect to the characterized TetR- and AraC-family transcriptional 
factors, respectively. SchA4 and SchA21 consist of the conserved DNA-binding domain 
of the TetR regulators, while SchA16 has the C-terminal conserved HTH DNA-binding 
domain. Asterisk (*) indicates positions which have a single, fully conserved residue. 
Colon (:) indicates conservation between groups of strongly similar properties. Period (.) 
indicates conservation between groups of weekly similar properties. GenBank accession 
numbers are: WP_010981587 (SAV_151), WP_052413891 (TcmR), WP_011028825 
(SCO3201), WP_108908224 (TdrK), CAH10095 (SchA4), CAA60451 (RapY), 
CCC55902 (ClmR1), AAD13556 (LanK), WP_030240800 (Au1R), WP_053125906 
(AlpW), WP_053125912 (AlpZ), Q9ZN78 (ArpA), WP_010982014 (SAV_576), 
AAK06798 (SimR), CAL99365 (SACE_0012), NP_733542 (SCO1712), 
WP_004193135 (TetR), BAG20734 (SgAtrA), EFE75762 (SrAtrA), CBA11576 
(SlgR1), AFU52889 (GouR), CAH10121 (SchA21), WP_069862081 (GdmRIII), 
WP_009951472 (SACE_7301), EDY64415 (SSDG_03033), WP_006124065 (DepR1), 
WP_003968987 (AdpA), AAP42877 (NanR4), CAH10107 (SchA16), CAA60472 




resistant exconjugants were obtained from intergenic conjugation between Streptomyces 
sp. SCC-2136 and E. coli ET12567/pRY19. The correct mutant was verified by PCR 
using vector- (RV-M and M13-47) and genome-specific primers (Fig. 9A). As illustrated 
in Fig. 9B, the 1.50 kb and 1.55 kb PCR products were amplified from the genome of 
Streptomyces sp. SCC-2136/ΔschA4, whereas the wild type genome did not yield these 
fragments. This indicated that the schA4 gene was successfully disrupted. 
 
 
FIG. 9. Illustration of the single crossover recombination strategy for disruption 
for schA4 (A) and PCR confirmation of gene disruption (B). M: DNA ladder. 1: 
Genomic DNA of wild type Streptomyces sp. SCC-2136 as template with the forward 
check primer and M13-47 universal primer. 2: Genomic DNA of Streptomyces sp. SCC-
2136 mutant strains with the forward check primer and M13-47 universal primer. 3: 
Genomic DNA of wild type Streptomyces sp. SCC-2136 as template with the RV-M 
universal primer and reverse check primer. 4: Genomic DNA of Streptomyces sp. SCC-




Upon confirmation of gene inactivation, the positive exconjugants were grown on 
YM plates supplemented with apramycin for product analysis. As shown in Fig. 10A, 
Streptomyces sp. SCC-2136/ΔschA4 showed the same product profile as the wild type. 
The major peak was isolated and characterized as Sch47554 by a comparison of its MS 
and NMR data (Figs. C1 and C2) with those reported. However, the titer of Sch47554 in 
Streptomyces sp. SCC-2136/ΔschA4 reached 27.94 mg/L, which is significantly higher 
than the wild type (6.72 mg/L) (Fig. 10B). This result suggests that SchA4 acts as a 
repressor, similar to most regulatory proteins in the TetR family (17,18,54-56). For 
instance, SAV576 negatively controls the biosynthesis of avermectin in S. avermetilis 
(18). Similarly, AlpZ is another TetR family transcriptional factor with a repressor role in 
the biosynthesis of angucyclinone antibiotic alpomycin in S. ambofaciens (17). 
To ensure that the above result was not due to a polar effect caused by insertion of 
the disruption plasmid into the gene cluster (Fig. 9A), we next overexpressed schA4 in 
Streptomyces sp. SCC-2136. Overexpression approach has been used to investigate the 
function of regulatory proteins. For instance, Yoo et al. overexpressed three regulatory 
genes (rapY, rapR and rapS) using the pSET152 integrative expression plasmid to 
understand the function of regulatory elements in rapamycin biosynthesis (56). Kuščer et 
al. also exploited a pSET152-based integrative expression system to overexpress 
regulatory proteins in rapamycin-producing wild type strain, which led to an increase in 
the titer of rapamycin (24). Thus, we used the pSET152 integrative expression system to 
overexpress the corresponding regulatory genes. First, the schA4 gene was ligated into 
pSET152 to yield pOKF10, which was subsequently introduced into Streptomyces sp. 




supplemented with apramycin for product analysis. As shown in Fig. 11A, Streptomyces 
sp. SCC-2136/OE-schA4 produced the same metabolites as the wild type. The titer of 
Sch47554 in this strain was determined to be 2.42 mg/L (Fig. 11B), which is much lower 
than the wild type. This result further supports that SchA4 is a repressor for the 
biosynthetic pathway of Sch47554. Enhanced expression of SchA4 would have down-
regulated the pathway, resulting in a lower production titer of the target compound. 
 
FIG. 10. Effects of disruption of schA4, schA16 and schA21 on the production of 
Sch47554. (A) HPLC analysis (420 nm) of the extracts of Streptomyces sp. SCC-2136 
wild type and mutant strains for schA4, schA16 and schA21. The peak at 37.9 min is the 
antifungal compound of Sch47554. (B) A comparison of the titers of Sch47554 in wild 
type Streptomyces sp. SCC-2136 with those in the mutants with disrupted schA4, schA16 
or schA21. 55186-WT: Streptomyces sp. SCC-2138 wild type strain, SchA4-KO: 
Streptomyces sp. SCC-2136/ΔschA4, SchA16-KO: Streptomyces sp. SCC-2136/ΔschA16, 
and SchA21-KO: Streptomyces sp. SCC-2136/ΔschA21. The average titers are shown at 




Identification of SchA16 as an AraC-family repressor and enhanced 
production of Sch47554 by disrupting schA16 
The multiple amino acid sequence alignment predicted that SchA16 is an AraC 
family transcriptional factor. Similar to other characterized AraC family regulators, 
SchA16 has 15 amino acid consensuses for the conserved DNA-binding domain. To 
understand its role in the biosynthesis of Sch47554, we used a similar approach to disrupt 
this gene. The correct exconjugant was selected by apramycin resistance and verified 
using PCR. Two fragments, 1.50 kb and 1.40 kb, respectively, were amplified from the 
genome of Streptomyces sp. SCC-2136/ΔschA16 using genome- and vector-specific 
primers, while the wild type gave no PCR products using the same primers (Fig. C3A). 
Production of Sch47554 by this mutant was confirmed by HPLC (Fig. 10A) and the titer 
of this compound was determined to be 17.43 mg/L (Fig. 10B). This represents a nearly 
200% increase compared to the wild type strain, suggesting that SchA16 plays a role of 
repressor in the biosynthesis of Sch47554. 
We then amplified the schA16 gene and ligated it into pSET152 to yield the 
overexpression plasmid pOKF11. This plasmid was introduced into Streptomyces sp. 
SCC-2136 to overexpress SchA16. Although this engineered strain produced Sch47554 
(Fig. 11A), the titer of this compound was only 1.78 mg/L (Fig. 11B), which is much 
lower than the wild type. This result was consistent with that from the disruption of 
schA16. In general, the AraC family regulators are considered as activators with some 
exceptions (11). For instance, NanR4 and RapG act as activator in the biosynthesis of 
nanchangmycin and rapamycin, respectively (24,26). However, SAV742 is a repressor in 




avermectin (25), same as what we observed in the disruption of schA16. Similar to the 
TetR family regulators, the AraC family regulators could exhibit both positive and 
negative roles in the secondary metabolite production. Our results support that SchA16 is 
a repressor in the biosynthetic pathway of Sch47554 and the disruption of this gene can 
be an effective approach for improving the production of angucyclines in this strain. 
 
 
FIG. 11. Effects of overexpression of schA4, schA16 and schA21 on the 
production of Sch47554. (A) HPLC analysis (420 nm) of the extracts of Streptomyces sp. 
SCC-2136 wild type and overexpression strains for schA4, schA16 and schA21, 
respectively. (B) A comparison of the titers of Sch47554 in wild type Streptomyces sp. 
SCC-2136 with those in the engineered strains overexpressing schA4, schA16 or schA21. 
55186-WT: wild type strain; SchA4-OE: Streptomyces sp. SCC-2136-SchA4 
overexpression strain; SchA16-OE: Streptomyces sp. SCC-2136-SchA16 overexpression 
strain; SchA21-OE: Streptomyces sp. SCC-2136-SchA21 overexpression strain. The 




Characterization of SchA21 as a TetR family activator and enhanced 
production of Sch47554 by overexpressing schA21 
BLAST analysis showed that SchA21 also belongs to the TetR family of 
transcriptional factors. To under its role in the biosynthesis of Sch47554, we disrupted 
this gene through the single crossover homologous recombination approach shown in Fig. 
9A. The genome of the resulting mutant was extracted and subjected to PCR verification. 
Using the genome- and vector-specific primers, we were able to amplify the 1.40 and 
1.25 kb fragments from the genome of Streptomyces sp. SCC-2136/ΔschA21, but none 
from the wild type (Fig. C3B), confirming that this strain is the correct mutant. Product 
analysis showed that this mutant did produce the same products as the wild type (Fig. 
10A), but Sch47554 was only produced at a very low level (0.39 mg/L, Fig. 10B), 
indicating that disruption of SchA21 has significantly repressed the biosynthetic pathway 
of Sch47554. This gene was then ligated into pSET152 to yield the overexpression 
plasmid pOKF12. Overexpression of this gene in Streptomyces sp. SCC-2136 led to 
significantly enhanced production of Sch47554, with a titer of 26.23 mg/L, as shown in 
Figs. 11A and 11B. The disruption and overexpression strains for SchA4 and SchA21 led 
to the opposite results even though both regulatory proteins are in the same family. The 
titer of Sch47554 increased significantly in the knockout strain for SchA4 by 
approximately 4-fold, whereas it was dramatically decreased when schA21 was disrupted 
(Fig. 10B). The overexpression strains for these TetR family transcriptional factors 
produced consistent results with the gene-disrupted strains. Therefore, it can be 
concluded that SchA21 serves as an activator of the Sch47554 biosynthetic pathway. 




TetR family transcriptional regulators that act as activators in the biosynthesis of 
secondary metabolites. As an example, SAV3818 cloned from high avermectin-
producing S. avermitilis ATCC31780 was overexpressed in the low avermectin-
producing S. avermitilis ATCC 31267, showing a stimulatory effect in the low 
avermectin-producing strain. In addition, the overexpression of SAV3818 stimulated 
actinorhodin production in both S. coelicolor M145 and S. lividans TK21, implying that 
this TetR-family transcriptional regulator might be a global up-regulator acting in 
antibiotic production in Streptomyces species (20). Another example is GdmRIII, which 
not only plays a positive regulatory role in the biosynthesis of geldanamycin, but also 
plays a negative role in elaiophylin biosynthesis in S. autolyticus CGMCC0516 (22). We 
successfully increased the titer of Sch47554 through the overexpression of the TetR 
family activator, SchA21. 
CONCLUSIONS 
In conclusion, the roles of three putative regulatory genes in the sch biosynthetic 
gene cluster were investigated for enhanced production of a pharmaceutically important 
angucycline. Gene disruption of schA4 and schA16 led to a significant increase in the 
production of angucyclines. In contrast, disruption of schA21 dramatically decreased the 
yield of Sch47554. The overexpression strains produced opposite results. Therefore, 
SchA4 and SchA16 were identified as repressors, while SchA21 acts as an activator. Our 
results demonstrated that both disruption of pathway repressors and overexpression of 
activators are effective ways to improve the production of target compounds in the 




the biosynthesis of Sch47554, which will facilitate further engineering of this producing 
strain for the efficient production of these medicinally important angucyclines. 
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CHAPTER IV DISCOVERY AND ENGINEERING OF AN ENDOPHYTIC 
PSEUDOMONAS STRAIN FROM TAXUS CHINENSIS FOR EFFICIENT 
PRODUCTION OF ZEAXANTHIN DIGLUCOSIDE‡ 
Abstract  
Endophytic microorganisms are a rich source of bioactive natural products. They 
are considered as promising biofertilizers and biocontrol agents due to their growth-
promoting interactions with the host plants and their bioactive secondary metabolites that 
can help manage the plant pathogens. In this study, I isolated an endophytic bacterium 
from the leaves of Taxus chinensis, which was identified as Pseudomonas sp. 102515 
based on the 16S rRNA gene sequence. Analysis of its secondary metabolites revealed 
that this endophytic strain produces zeaxanthin diglucoside as a major product, a 
promising antioxidant natural product that belongs to the family of carotenoids. A 
carotenoid (Pscrt) biosynthetic gene cluster was amplified from this strain, and the 
functions of PsCrtI and PsCrtY in the biosynthesis of zeaxanthin diglucoside were 
confirmed in Escherichia coli BL21(DE3). The entire Pscrt biosynthetic gene cluster was 
successfully reconstituted in E. coli BL21(DE3) and Pseudomonas putida KT2440. The 
engineered strain of P. putida KT2440 produced zeaxanthin diglucoside at 144 ± 4 mg/L 
in SOC medium supplemented with 0.5% glycerol at 23 C, while the titer of zeaxanthin 
diglucoside in E. coli BL21(DE3) was only 2 mg/L. The production of zeaxanthin 
diglucoside in Pseudomonas sp. 102515 was improved through the optimization of 
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fermentation conditions such as medium, cultivation temperature and cultivation time. 
The highest titer under the optimized conditions reached 206 mg/L. The engineered strain 
of P. putida KT2440 produced zeaxanthin diglucoside at 121 mg/L in SOC medium 
supplemented with 0.5% glycerol at 18 C, while the yield of zeaxanthin diglucoside in 
E. coli BL21(DE3) was only 2 mg/L. To further enhance the production, I introduced an 
expression plasmid harboring the Pscrt biosynthetic gene cluster into Pseudomonas sp. 
102515. The titer in this engineered strain reached 380 mg/L, 85% higher than the wild 
type. Through PCR, I also discovered the presence of a turnerbactin biosynthetic gene 
cluster in Pseudomonas sp. 102515. Turnerbactin was reported to be involved in nitrogen 
fixation, suggesting that this endophytic strain might have a role of promoting growth of 
the host plant. Therefore, in addition to producing zeaxanthin diglucoside, Pseudomonas 
sp. 102515 might also be utilized as a plant-promoting strain for agricultural applications.  
INTRODUCTION 
Nature provides a huge repertoire of bioactive molecules from various living 
organisms. As such, natural products are a major source of new drugs. Microorganisms 
are known to produce many pharmaceuticals such as lovastatin (anti-cholesterol), 
penicillin (antibacterial) and vancomycin (antibacterial). There is an estimated more than 
99 per cent of microbial species left undiscovered in the world (1). Therefore, 
microorganisms remain an underexplored source of bioactive natural products. In 
particular, endophytes hold a huge potential for the discovery of natural products with 
pharmaceutical importance (2). Endophytes, microorganisms (bacteria and fungi) that 




host, are potential sources of novel natural products with applications in medicine, 
agriculture, and industry (3,4). They have been isolated from many important medicinal 
plants, weeds, and ornamental and fruit trees (2). Endophytes enter plants through the 
roots and the aerial portions of plants, such as leaves, flowers, stems and cotyledons (5). 
Upon entering the host, they reside within cells or the intercellular spaces or the vascular 
system (6). Some of the endophytes can exhibit plant growth-promoting effects and 
protect plants from biotic and abiotic stresses under different environmental conditions. 
Thus, they are considered as endosymbiotic microorganisms with potential agricultural 
applications such as biofertilizers and biocontrol agents (6-9). 
Another important aspect is that the endophytes are known to produce a wide 
variety of natural products. For example, ecomycins produced by Pseudomonas 
viridiflava, are a family of novel lipopeptides and consist of some unusual amino acids 
including homoserine and β-hydroxy aspartic acid (10). Another example is 
pseudomycins, which represent a group of peptide antifungal compounds isolated from 
the plant-associated bacterium Pseudomonas syringae (11). New microbial species can 
sometimes lead to the rediscovery of known natural products as happened in the example 
of camptothecin, a potent antineoplastic agent. Camptothecin was originally isolated from 
the wood of Camptotheca acuminate. Interestingly, several endophytes such as 
Entrophospora infrequens and Nodulisporium sp. were reported to produce camptothecin 
(12), representing an alternative and potential mean for the production of this 
pharmaceutically important molecules. 
Carotenoids are isoprenoid pigments that are seen throughout the nature. They are 




and archaea (13). Carotenoids exhibit diverse biological functions in different organisms 
that either produce or consume carotenoids. They serve as accessory pigments in the light 
harvesting center of phototrophic organisms (14). The primary roles of carotenoids in 
non-phototrophic organisms are membrane stability and the relief of oxidative stress (15). 
Additionally, carotenoids have been used in various applications, ranging from food 
colorants and feed supplements to nutritional and cosmetics purposes (16). This family of 
natural products has shown a variety of biological activities, such as antioxidant, 
anticancer, and anti-inflammatory properties. They are also used as precursors for the 
synthesis of vitamin A and as nutritional factors for the prevention of chronic diseases 
(17,18). Due to the negative impacts of synthetic coloring agents on human health (e.g., 
toxicity, hyperallergenicity, and carcinogenicity) and the increase in the consumer 
demand for natural and health-promoting food ingredients, the utilization of carotenoids 
as colorants and supplements is rising in the food, cosmetics, nutraceutical and 
pharmaceutical industries, with an expected global market value of $1.8 billion in 2019 
(19,20). 
Even though more than 750 different carotenoids were isolated from nature, all 
carotenoids share a linear, conjugated chromophore backbone and a common early 
biosynthetic pathway (Fig. 12). Carotenoid biosynthesis typically begins with the 
isomerization of isopenthyl diphosphate (IPP) from the mevalonate pathway to yield 
dimethylallyl diphosphate (DMAPP), catalyzed by the IPP isomerase (Idi). Geranyl 
diphosphate (GPP) is synthesized through the head-to-tail condensation of IPP and 
DMAPP. Addition of IPP to GPP generates farnesyl pyrophosphate (FPP) formation and 




diphosphate synthase (CrtE). Phytoene synthase (CrtB) catalyzes the head-to-head 
condensation of two GGPPs to phytoene. Phytoene desaturase (CrtI) extends the double 
bond conjugation of phytoene to yield lycopene. Terminal β-cyclization catalyzed by 
lycopene β-cyclase (CrtY) results in the formation of β-carotene, which is subsequently 
hydroxylated by β-carotene hydroxylase (CrtZ), yielding zeaxanthin. Zeaxanthin can be 
further modified by different tailoring enzymes to yield a variety of carotenoids. For 
example, it can be glycosylated by a glycosyltransferase (CrtX) to generate zeaxanthin 
diglucoside (21-24). 
In this study, my primary goal was to isolate an endophytic bacterium with the 
purpose of discovering new natural products and/or finding a new effective mean to 
produce known natural products. I isolated an endophytic Pseudomonas strain, named 
Pseudomonas sp. 102515, from the leaves of the yew tree. This bacterium was found to 
produce zeaxanthin diglucoside as the major product, and a complete carotenoid (Pscrt) 
biosynthetic gene cluster was discovered in Pseudomonas sp. 102515. Two biosynthetic 
genes from this gene cluster, PscrtI and PscrtY, were functionally characterized. The 
entire carotenoid (Pscrt) biosynthetic gene cluster was amplified from the endophytic 
strain and successfully expressed in two heterologous hosts, E. coli BL21 (DE3) and 
Pseudomonas putida KT2440. Additionally, the production of zeaxanthin diglucoside in 
Pseudomonas sp. 102515 was significantly improved by optimizing the fermentation 
conditions, with a titer of 206 ± 6 mg/L. Furthermore, when a plasmid harboring the 
entire Pscrt gene cluster was introduced into Pseudomonas sp. 102515, the titer of 
zeaxanthin diglucoside reached 380 ± 12 mg/L, 85% higher than the wild type strain. 







FIG. 12. Proposed biosynthetic pathway of zeaxanthin diglucoside in 
Pseudomonas sp. 102515. The involved enzymes include isopentenyl-diphosphate delta-




(PsCrtB), lycopene synthase (PSCrtI), lycopene cyclase (PsCrtY), β‐carotene 
hydroxylase (PsCrtZ), and zeaxanthin glucosyltransferase (PsCrtX). 
 
MATERIALS AND METHODS 
Bacterial strains, media and culture conditions 
E. coli XL1-Blue, which was routinely grown in LB (Luria-Bertani) medium at 37 
ºC, was used for general genetic manipulations. Pseudomonas sp. 102515 was grown in 
LB overnight for genomic DNA (gDNA) extraction. LB, SOB, SOC, 2YT, TB, 2TB 
and superbroth media (Recipes for media are in Table D1) were tested for the production 
of zeaxanthin diglucoside by Pseudomonas sp. 102515. E. coli BL21(DE3) and P. putida 
KT2440 were utilized for heterologous expression and co-expression studies. All wild 
type and engineered bacterial strains are listed in Table 4. Chloramphenicol (25 μg/mL), 
ampicillin (50 μg/mL) and kanamycin (50 and 30 μg/mL) were supplemented when 
appropriate. The concentrations of kanamycin for engineered E. coli and Pseudomonas 
strains are 50 and 30 μg/mL, respectively. 
Isolation of endophytic bacteria from Taxus chinensis 
The leaves were collected from a cultivated shrub of T. chinensis on the Logan 
campus of Utah State University (Latitude: 41.7424, Longitude: -111.8080). A voucher 
specimen is deposited at the Intermountain herbarium, accession number UTC00282046. 
The collected leaves were thoroughly washed in running water. The disinfection and 
isolation were performed according to de Oliveira Costa et al. with minor modifications 




for 2 minutes three times, followed by rinsing with 70% ethanol three times. Then, the 
leaves were dipped into sterile distilled water for a few minutes and rinsed with sterile 
distilled water. This process was repeated three times. To confirm the disinfection 
protocol, aliquots of the sterile water used in the final rinse were plated in LB plates at 28 
ºC for 7 days and the plates were examined for the presence or absence of any microbial 
colonies. 
The disinfected leaves were grounded with 6 mL of an aqueous NaCl solution 
(0.85 %) using a sterile mortar and pestle. The tissue extract was subsequently incubated 
at 28 ºC for 3 hours to allow the complete release of endophytic microorganisms from the 
host tissue. For the isolation of endophytic bacteria, the tissue extract was diluted with the 
NaCl solution and plated on LB plates with different dilutions. The plates were incubated 
at 28 ºC for around a week. Promising colonies were selected and streaked on fresh LB 
plates for the isolated bacteria. 
TABLE 4 Strains used in Chapter 4. 
Strain Description Source 
E. coli XL1-Blue 
endA1 gyrA96(nalR) thi-1 recA1 relA1 lac 
glnV44 F'[ ::Tn10 






E. coli BL21(DE3) 




T7p07 ind1 sam7 nin5]) [malB+]K-12(λ
S) 
Novagen 
Pseudomonas sp. 102515 





Heterologous host for expression of the 





E. coli BL21(DE3)/ 
pAC-PHYTipi 
E. coli BL21(DE3) expressing the 
phytoene biosynthetic genes from pAC-
PHYTipi (phytoene producing) 
This study 
E. coli BL21(DE3)/ 
pAC-PHYTipi+pOKF89 
E. coli BL21(DE3) expressing the 
phytoene biosynthetic genes from pAC-
PHYTipi with PscrtI (lycopene 
producing) 
This study 
E. coli BL21(DE3)/ 
pAC-LYCipi 
E. coli BL21(DE3) expressing the 
lycopene biosynthetic genes from pAC-
LYCipi (lycopene producing) 
This study 
E. coli BL21(DE3)/ 
pAC-LYCipi+pOKF91 
E. coli BL21(DE3) expressing the 
lycopene biosynthetic genes from pAC-
LYCipi with PscrtY (β-carotene 
producing) 
This study 
E. coli BL21(DE3)/ 
pAC-BETAipi 
E. coli BL21(DE3) expressing the β-
carotene biosynthetic genes from pAC-
BETAipi (β-carotene producing)  
This study 
E. coli BL21(DE3)/ 
pAC-ZEAXipi+pOKF72 
E. coli BL21(DE3) expressing the β-
carotene biosynthetic genes from pAC-
ZEAXipi with CrtX (zeaxanthin 
diglucoside producing) 
This study 
E. coli BL21(DE3)/ 
pAC-EHER 
E. coli BL21(DE3) expressing the 
zeaxanthin diglucoside biosynthetic genes 





E. coli BL21(DE3) expressing the Pscrt 
biosynthetic gene cluster from 




Pseudomonas putida KT2440 expressing 
the Pscrt biosynthetic gene cluster from 




Engineered Pseudomonas sp. 102515 
strain with an additional Pscrt 






General genetic manipulation and PCR 
Standard molecular biology protocols were performed as previously described 
(26). Genomic DNA of Pseudomonas sp. 102515 was extracted with a ZR 
Fungal/Bacterial DNA Miniprep Kit (Irvine, CA, USA). Plasmid DNA extraction from E. 
coli cells was performed using a Thermo Scientific GeneJET Plasmid Miniprep Kit 
(Logan, UT, USA). PCR reactions were performed with an Arktik™ Thermal Cycler 
(Thermo Scientific) using Phusion DNA polymerase (Thermo Scientific, Logan, UT, 
USA). Primers were ordered from Thermo Scientific and dissolved in TE buffer to the 
final concentration of 100 ng/mL. 
Identification and phylogenetic analysis of endophytic bacterium 
The partial 16S rRNA gene fragment was PCR amplified from the gDNA of 
Pseudomonas sp. 102515 using the 16S universal primers of 
GGCTACCTTGTTACGACTTC and AGTTTGATCCTGGCTCAG (27). The PCR 
product was sent out for sequencing by Sanger's method. The 16S rRNA gene sequence 
was deposited into NCBI Genbank database under the accession number of MK610450 
(Sequence D1). BLAST analysis of this 16S rDNA sequence was performed using the 
16S ribosomal RNA sequences database on NCBI. Using the 16S rRNA sequences of 
relative bacteria to our isolated endophytic bacterium from BLAST analysis, I created 
phylogenetic tree by the neighbor-joining method using an online platform 
(https://itol.embl.de/) (28). Both BLASTn analysis and phylogenetic tree indicated the 
bacterial strains closely related to our strain. For physiological characteristics, scanning 




Amplification and annotation of the Pscrt biosynthetic gene cluster 
The colonies of Pseudomonas sp. 102515 on LB agar plates showed a yellow 
color. LC-MS analysis of the methanol extract of the cells confirmed that zeaxanthin 
diglucoside was produced. To discover the carotenoid (Pscrt) biosynthetic gene cluster in 
Pseudomonas sp. 102515, I first analyzed the genome of Pseudomonas psychrotolerans 
(GenBank accession number: NZ_CP018758), which is the closest relative of our strain 
based on the phylogenetic analysis. I used an online genome analysis platform, 
AntiSMASH, and found a complete crt biosynthetic gene cluster in P. psychrotolerans 
responsible for the biosynthesis of zeaxanthin diglucoside. I designed two sets of primers 
(primers 3-6, Table D2) based on the DNA sequence of this crt gene cluster. Briefly, the 
whole Pscrt gene cluster was divided into two fragments, which were PCR amplified 
from the gDNA of Pseudomonas sp. 102515 using the primers (primers 3 and 4 for 
fragment A, and primers 5 and 6 for fragment B) listed in Table D2. Fragments A and B 
were first ligated into pJET1.2, yielding pOKF163 and pOKF166 (Table 5), respectively. 
These two plasmids were sent out for DNA sequencing to obtain the whole DNA 
sequence of the Pscrt gene cluster using the walking primers (primes 7-16) listed in Table 
D2. The whole DNA sequence of Pscrt biosynthetic gene cluster from Pseudomonas sp. 
102515 was deposited into GenBank under the accession number of MK613929 
(Sequence D2). 
Construction of plasmids for functional characterization of PsCrtI and 
PsCrtY  




biosynthetic genes in E. coli. crtX (glycosyltransferase) was PCR amplified using the 
primers 17 and 18 (Table D2) from pAC-EHER, which was a gift from Francis X 
Cunningham Jr (Addgene plasmid # 53262). PCR product was directly ligated into the 
cloning vector, pJET1.2, yielding pOKF55 (Table 5), which was sent out for DNA 
sequencing using Sanger’s method (Eton Bioscience, San Diego, CA, USA). crtX was 
excised with NcoI and HindIII from pOKF55 and ligated into pET28a(+) between the 
same sites to yield pOKF63 (Table 5). pOKF63 and pAC-ZEAXipi (Addgene plasmid # 
53287) were introduced into E. coli BL21(DE3) for co-expression. The engineered strain 
was grown in LB medium with 50 µg/mL kanamycin and 25 µg/mL chloramphenicol, 
and induced with 200 μM of IPTG for product analysis.  
To replace the T7 promoter in pET28a(+) with a strong constitutive promoter, 
J23119, I redesigned the forward primer for crtX by including the J23119 promoter and 
B0034 ribosome binding site before the start codon (Table D2). I re-amplified crtX with 
J23119 and B0034 from pAC-EHER using this new forward primer and previous reverse 
primer (primers 19 and 20). The new PCR product was ligated into pJET1.2 (pOKF69, 
Table 5) and the sequence was confirmed by sequencing. Subsequently, crtX with J23119 
and B0034 was excised from pOKF69 using BglII and HindIII, and then ligated into 
pET28a(+) between the same sites to yield pOKF72 (Table 5). The coexpression of 
pOKF72 and pAC-ZEAXipi (Addgene plasmid # 53287) in E. coli BL21(DE3) did 
produce zeaxanthin diglucoside, which was confirmed by HPLC through the comparison 
of retention time and UV-spectra with E. coli BL2(DE3) harboring pAC-EHER. PscrtI 
and PscrtY were PCR amplified from the genomic DNA of Pseudomonas sp. 102515 




in Table D2 and were subsequently ligated into pJET1.2 to yield pOKF85 and pOKF88 
(Table 5), respectively. Upon confirmation of sequences by Sanger’s method, PscrtI and 
PscrtY were transferred into pET28a(+) with J23119 and B0034 using NdeI and HindIII 
sites to yield pOKF89 and pOKF91 (Table 5), respectively. PsCrtI (pOKF89) and PsCrtY 
(pOKF91) were separately co-expressed with pAC-PHYTipi (Addgene plasmid #: 
53283) and pAC-LYCipi (Addgene plasmid #: 53279) in E. coli BL21(DE3), 
respectively. 
TABLE 5 Plasmids used in Chapter 4. 
Plasmid  Description Source 
pJET1.2 Cloning vector Fermentas 
pET28a(+) E. coli expression plasmid, pBR322 Novagen 
pACYC184 E. coli expression plasmid, p15A ATCC 37033 





















Expression plasmid for Pseudomonas putida 
KT2440 that contains the mevalonic acid 
(MVA) pathway genes 
(78) 




pOKF63 crtX gene from pOKF55 in pET28a(+) This study 
pOKF69 
crtX gene with the J23119 constitutive 




crtX gene with the J23119 constitutive 




PscrtI gene cloned from Pseudomonas sp. 
102515 in pJET1.2 
This study 
pOKF88 
PscrtY gene cloned from Pseudomonas sp. 
102515 in pJET1.2 
This study 
pOKF89 
PscrtI gene with the J23119 constitutive 




PscrtY gene with the J23119 constitutive 








The Pscrt biosynthetic gene cluster fragment B 
in pJET1.2 
This study 
pOKF169 The Pscrt biosynthetic gene cluster in pJET1.2 This study 
pOKF173 








tnbA gene cloned from Pseudomonas sp. 
102515 in pJET1.2 
This study 
pOKF192 




Heterologous expression of the Pscrt gene cluster from Pseudomonas sp. 
102515 in E. coli BL21(DE3) and P. putida KT2440 




strain, I first excised fragment A from pOKF163 using NheI and MfeI and ligated it into 
pOKF166 that contains fragment B between the same sites to yield pOKF169 (Table 5), 
which harbors the entire Pscrt gene cluster in pJET1.2. Due to a high copy number of 
pJET1.2, I then ligated the Pscrt gene cluster excised from pOKF169 using the SpeI and 
HindIII sites into pET28a(+) digested with NheI and HindIII (pOKF173, Table 5). Since 
pET28a(+) has a relatively higher copy number, I decided to also ligate the Pscrt gene 
cluster from pOKF169 into pACYC184 between the XbaI and HindIII sites to yield 
pOKF184 (Table 5). The corresponding expression plasmids including pOKF173 and 
184, were transferred into E. coli BL21(DE3) for heterologous expression of the Pscrt 
biosynthetic gene cluster.  
I also constructed an expression plasmid for expression of the Pscrt gene cluster 
in P. putida KT2440. The pMIS1-MVA-GES plasmid was generously provided by Jens 
Schrader and Josef Altenbuchner at Dechema-Forschungsinstitut and University of 
Stuttgart, respectively (78). The whole Pscrt gene cluster was excised from pOKF169 
using the SpeI and PmeI sites and ligated into the pMIS1-MVA-GES plasmid digested 
with AvrII and PmeI to yield pOKF192 (Table 5). pOKF192 was introduced into P. 
putida KT2440 by electroporation as described in the literature (30). Briefly, P. putida 
KT2440 was grown until the OD600 reached 0.4 at 28 C. The cells were immediately 
placed on ice and harvested by centrifugation. Then, the cells were washed three times 
with 300 mM sterile sucrose solution and re-suspended in 100 µL of 300 mM sucrose 
solution. The cells were mixed with pOKF192 and the mixture was transferred into a pre-




were used for electroporation: set voltage - 2.5 kV (12.5 kV/cm); capacitor - 25 µF. After 
electroporation, 900 µL of LB broth was immediately added to the cuvette. The mixture 
was then transferred into a culture tube, which was incubated at 28 C with shaking (250 
rpm) for 2 h. Finally, the cells were plated on LB agar plates with 30 µg/mL kanamycin 
and incubated at 28 C. The transformants were picked and grown in LB with kanamycin 
for product analysis. The same electroporation protocol was followed to introduce 
pOKF192 into Pseudomonas sp. 102515. 
Discovery of a turnerbactin biosynthetic gene cluster in Pseudomonas sp. 
102515 by PCR 
To find out whether Pseudomonas sp. 102515 contains a turnerbactin biosynthetic 
gene cluster, the tnbA gene was cloned from the genomic DNA of Pseudomonas sp. 
102515 using primers 25 and 26 listed in Table D2. The PCR product was ligated into the 
pJET1.2 cloning vector to yield pOKF187 (Table 5), which was subsequently sent out for 
sequencing (Sequence D3).  
Optimization of carotenoid production and extraction and HPLC-MS 
analysis of zeaxanthin diglucoside 
For Pseudomonas sp. 102515, different culture media were tested to increase the 
yield of zeaxanthin diglucoside. Upon the determination of a suitable medium, I 
investigated the effect of glycerol supplementation as an additional carbon source. 
Cultivation time and temperature were also tested for an improved production of 
carotenoids. I also analyzed the yield of zeaxanthin diglucoside in heterologous 




The wild type and engineered strains were typically cultured in 250-mL flasks 
containing 50 mL of medium. The cultures were centrifuged at 3,500 rpm for 8 min to 
harvest the cells and the cell pellets were suspended in 50 mL of methanol. The cell 
suspension in methanol was sonicated for 5 min to extract carotenoids. After 
centrifugation at 3,500 rpm for 8 min, the resulting extract was dried in vacuo, and the 
residues were redissolved in a DMSO-methanol mixture (10% v/v) for HPLC-MS 
analysis with a gradient mobile phase of acetonitrile-water from 50 % to 90 % over 45 
min at 1 mL/min. Low-resolution ESI-MS spectra were obtained on an Agilent 6130 LC-
MS to confirm the molecular weights of carotenoids. For co-expression experiments, I 
used a different HPLC condition for better separation of phytoene, lycopene and -
carotene. For this HPLC method, I used an isocratic elution system of methanol-
tetrahydrofuran (6/4, v/v) over 45 min at 1 mL/min. 
Zeaxanthin diglucoside was subsequently purified by HPLC with an Agilent 
Eclipse XDB-C18 column (5 μm, 250 mm × 4.6 mm) for the standard curve preparation. 
The standard curve was prepared with methanol as the solvent using UV 
spectrophotometer at 456 nm to calculate the yields in the optimization experiments. All 
crude extracts before drying in vacuo were directly measured using spectrophotometer to 
calculate the yield values. All samples were done in three replicates. 
RESULTS 
Identification and phylogenetic analysis of endophytic bacteria  
I isolated an endophytic bacterium from the leaves of Taxus chinensis, whose 




gene fragment by PCR using a set of universal primers. The gene sequence of this 
fragment was subjected to BLAST analysis, with the 16S ribosomal RNA sequences 
(bacteria and archaea) as the reference database. The BLASTn analysis revealed that 
there are three Pseudomonas strains with 99 % identity and coverage. Some other 
Pseudomonas strains (P. stutzeri, P. indoloxydans, P. luteola, etc.) also have 99 % 
coverage but are 96 % identical to our endophytic isolate. Using an online platform 
(https://itol.embl.de/), I constructed a phylogenetic tree using the neighbor-joining 
method (Fig. 13A). The phylogenetic tree indicated that P. psychrotolerans is the closest 
relative to our isolate. P. oryzihabitans and P. oleovorans are also closely related to this 
endophytic strain. I also looked into the physiology of our isolate under SEM (Fig. 13B) 
and confirmed that it is a rod-shaped bacterium. Additionally, it is a non-spore-forming 
and a yellow-pigment-producing bacterium. The closest relative bacterium, P. 
psychrotolerans, was also reported as a yellow-pigmented bacterium (31). All these 
physiological characteristics and genetic analysis (phylogenetic relationships) indicated 












FIG. 13. Identification of Pseudomonas sp. 102515. (A) A phylogenetic tree 
constructed based on the 16S rRNA sequences of Pseudomonas strains from BLASTn 
analysis. It estimates the relationship between strain 102515 and other Pseudomonas 
strains that shared the highest 16S rRNA gene sequence similarities. Sequences of 
reference species were obtained from GenBank. P. luteola (NR_114215), P. asuensis 
(NR_136445), P. duriflava (NR_044390), P. benzenivorans (NR_116904), P.stutzeri 
(NR_041715), P. songnenensis (NR_148295), P. alcaligenes (NR_113646), P. otitidis 
(NR_043289), P. aeruginosa (NR_117678), P. alcaliphila (NR_114072), P. 









P. oryzihabitans (NR_114041), P. psychrotolerans (NR_042191.1). (B) SEM electron 
micrograph of Pseudomonas sp. 102515. The bacterium was fixed with 2 % 
glutaraldehyde in 0.1 % HEPES buffer overnight. The samples were subjected to alcohol 
series dehydration (50-100 % ethanol) and then chemically dried using 
hexamethyldisilazane. 
 
Amplification and analysis of a zeaxanthin diglucoside biosynthetic gene 
cluster from Pseudomonas sp. 102515 
As described above, P. psychrotolerans is the closest relative strain to 
Pseudomonas sp. 102515. The genome of this strain is available at NCBI under the 
accession number, NZ_CP018758. I analyzed the genome of P. psychrotolerans with the 
help of AntiSMASH online genome analysis platform. Four biosynthetic gene clusters 
were identified. The first one is a nonribosomal peptide synthetase (NRPS)-type gene 
cluster with a 50 % similarity to the known taiwachelin biosynthetic gene cluster. Even 
though this gene cluster was identified as a NRPS type gene cluster, it includes the 
turnerbactin (tnb) biosynthetic gene cluster. Turnerbactin was reported to have an 
important role in the plant-microbe interactions (32). In order to find out whether a tnb 
gene cluster is present in Pseudomonas sp. 102515, I amplified the tnbA gene from its 
genomic DNA using a pair of primers designed based on the genome of P. 
psychrotolerans. The sequence of tnbA was provided in the supplementary information 
(Sequence D3). The second gene cluster is an arylpolyene (APE)-type biosynthetic gene 
cluster from which 40% of genes show similarity to the genes from the characterized 




bacteria, including Pseudomonas strains (33). In addition to a siderophore biosynthetic 
gene cluster, genome analysis revealed that P. psychrotolerans has a carotenoid (crt) 
biosynthetic gene cluster. The genes from this crt gene cluster is similar to those found in 
the crt gene cluster from Pantoea agglomerans. It contains crtE, idi, crtX, crtY, crtI, crtB 






FIG. 14. Production of zeaxanthin diglucoside by Pseudomonas sp. 102515. (A) 
HPLC analysis (460 nm) of zeaxanthin diglucoside by Pseudomonas sp. 102515. (i) 
Pseudomonas sp. 102515; (ii) E. coli BL21(DE3)/pAC-EHER. (B) Comparison of the 
UV spectra of the major product of Pseudomonas sp. 102515 and E. coli 
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BL21(DE3)/pAC-EHER. (C) ESI-MS(-) spectrum of the major product of Pseudomonas 
sp. 102515. 
 
To find out what yellow compound Pseudomonas sp. 102515 produced, I 
extracted the cells with methanol/chloroform (2:1, v/v) and analyzed the products by LC-
MS. The extract of Pseudomonas sp. 102515 showed a major peak at 18.2 min (Fig. 
14A). Based on its UV and MS spectra (Figs. 14B and 14C), this compound was 
characterized as zeaxanthin diglucoside. Furthermore, this peak has the same retention 
time and UV spectrum as zeaxanthin diglucoside produced by E. coli BL21(DE3)/pAC-
EHER (35). Therefore, I confirmed that the yellow pigment from this endophyte is 
zeaxanthin diglucoside. 
TABLE 6 List of genes from the Pscrt biosynthetic gene cluster in Pseudomonas 
sp. 102515. 
Gene Size (aa) Function 
orf1 314 YegS-like lipid kinase 
PscrtZ 174 Beta-carotene hydroxylase 
orf2 176 Gluconate 2-dehydrogenase subunit 
PscrtB 311 15-cis-phytoene synthase 
PscrtI 500 Phytoene desaturase 
PscrtY 397 Lycopene cyclase 
PscrtX 431 Zeaxanthin glycosyltransferase 
Psidi 349 Isopentenyl-diphospahte delta-isomerase 
PscrtE 293 Geranylgeranyl diphosphate synthase 
 
Based on the sequence of the crt gene cluster in P. psychrotolerans, I designed 
two sets of primers and successfully amplified a carotenoid (Pscrt) biosynthetic gene 




cluster were analyzed and annotated (Table 6), and based on the predicted functions of 
these genes, I propose that this gene cluster is responsible for the biosynthesis of 
zeaxanthin diglucoside. 
Functional analysis of two carotenoid biosynthetic genes from the isolated 
strain 
To confirm the functions of the carotenoid biosynthetic genes from Pseudomonas 
sp. 102515, it is necessary to develop an effective expression system for carotenoid 
biosynthetic enzymes in E. coli. I first ligated the crtX (zeaxanthin glucosyltransferase) 
gene from pAC-EHER into pET28a(+) to yield pOKF63. However, co-expression of 
pOKF63 and zeaxanthin-producing pAC-ZEAXipi in E. coli BL21(DE3) did not produce 
zeaxanthin diglucoside upon induction with 200 μM of IPTG. I next replaced the T7 
promoter in pET28a(+) with a strong constitutive promoter J23119 and the B0034 
ribosome binding site (pOKF72). The coexpression of pOKF72 and pAC-ZEAXipi in E. 
coli BL21(DE3) did produce zeaxanthin diglucoside, which was confirmed by HPLC 
through the comparison of retention time and UV spectra of the authentic sample 
obtained from E. coli BL21(DE3) harboring pAC-EHER (data not shown). I next used 
this system to test the functions of two selected biosynthetic genes in the Pscrt gene 
cluster. PsCrtI and PsCrtY were chosen as their functions can be easily observed by the 
color change in the products. Co-expression of the phytoene-producing plasmid pAC-
PHYTipi with PsCrtI in E. coli BL21(DE3) led to the production of lycopene. I observed 
the color change from colorless cell pellets (E. coli BL21(DE3)/pAC-PHYTipi) to red 




confirmation, I compared the extract of this engineered strain with those of the negative 
(pAC-PHYTipi) and positive (pAC-LYCipi) controls by HPLC (Fig. 15A), which clearly 
revealed that lycopene was formed. This was supported by the UV spectra (Fig. 15B). 
This result confirmed that PsCrtI is a phytoene desaturase that converts phytoene to 
lycopene (Fig. 12). Similarly, I also confirmed the function of PsCrtY as a lycopene 
cyclase in E. coli BL21(DE3) by co-expression pAC-LYCipi with PsCrtY. I observed the 
color change from red to yellow due to the conversion of lycopene into β-carotene by 
PsCrtY (Fig. 16A). Production of β-carotene was further confirmed by its retention (Fig. 







FIG. 15. Functional identification of PsCrtI as a phytoene desaturase. (A) HPLC 
analysis of lycopene production through co-expression of PsCrtI with the phytoene 
biosynthetic enzymes. (i) E. coli BL21(DE3)/pAC-PHYTipi (negative control) producing 
phytoene (retention time: 17.5 min, 280 nm), (ii) E. coli BL21(DE3)/pAC-
PHYTipi+pOKF89 (pAC-PHYTipi+PsCrtI) producing lycopene (retention time: 14.8 
min, 460 nm), (iii) E. coli BL21(DE3)/pAC-LYCipi (positive control) producing 
lycopene (retention time: 14.8 min, 460 nm). Color change of harvested cells due to the 
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co-expression of PsCrtI with pAC-PHYTipi in E. coli BL21(DE3). (B) A comparison of 
the UV spectra of lycopene produced by E. coli BL21(DE3)/pAC-PHYTipi+pOKF89 





FIG. 16. Functional identification of PsCrtY as a lycopene cyclase. (A) HPLC 
analysis (460 nm) of -carotene production through co-expression of PsCrtY with the 
lycopene biosynthetic enzymes.  (i) E. coli BL21(DE3)/pAC-LYCipi (negative control) 
producing lycopene (retention time: 14.8 min), (ii) E. coli BL21(DE3)/pAC-
LYCipi+pOKF91 (pAC-LYCipi+PsCrtY) producing β-carotene (retention time: 13.3 
min), (iii) E. coli BL21(DE3)/pAC-BETAipi (positive control) producing β-carotene 
(retention time: 13.3 min). Color change of harvested cells due to the co-expression of 
PsCrtY with pAC-LYCipi in E. coli BL21(DE3) is shown on the right. (B) A comparison 
of the UV spectra of β-carotene produced by E. coli BL21(DE3)/pAC-LYCipi+pOKF91 
with β-carotene produced by the positive control and lycopene produced by the negative 
control. 
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Heterologous expression of the Pscrt gene cluster in E.coli BL21(DE3) and 
Pseudomonas putida KT2440 
Identification of PsCrtI and PsCrtY further suggested that this gene cluster is 
responsible for the biosynthesis of zeaxanthin diglucoside in Pseudomonas sp. 102515. 
Instead of characterizing each of the remaining genes in this gene cluster, I attempted to 
express the entire gene cluster in a heterologous host. I first transferred the whole Pscrt 
gene cluster into the pET28a(+) expression vector. Heterologous expression of the whole 
Pscrt gene cluster using the pET28a(+) expression system did not produce detectable 
amounts of zeaxanthin diglucoside. Then, I cloned the Pscrt gene cluster into a 
pACYC184 based expression system that has been previously used for the heterologous 
production of carotenoids in E. coli (35). Expression of the Pscrt gene cluster in E. coli 
BL21(DE3) led to the production of zeaxanthin diglucoside (Fig. 17), which confirmed 
that this gene cluster is indeed responsible for the biosynthesis of this glycosylated 
carotenoid. However, the yield of zeaxanthin diglucoside was very low in E. coli 
BL21(DE3) as the cells only showed a slight yellow color. I figured that P. putida 
KT2440 might be a better host since it belongs to the genus of Pseudomonas. To this end, 
I cloned the Pscrt biosynthetic gene cluster into the pMIS1-mva vector, and expressed the 
resulting plasmid (pOKF192) in P. putida KT2440. Expression of this plasmid in P. 
putida KT2440 was deemed successful by observing the bright yellow color of the cells, 





FIG. 17. Heterologous reconstitution of the zeaxanthin diglucoside biosynthetic 
pathway in E. coli BL21(DE3) and Pseudomonas putida KT2440. Shown are HPLC 
traces (460 nm) of the extracts of Pseudomonas sp. 102515 (i), E. coli 
BL21(DE3)/pOKF184 (ii), and P. putida KT2440/pOKF192 (iii). 
 
Enhanced production of zeaxanthin diglucoside in Pseudomonas sp. 102515 
For yield optimization studies, I used a UV spectrophotometer to measure the 
amount of zeaxanthin diglucoside in the extracts at 456 nm, which is the maximum 
wavelength for zeaxanthin diglucoside as applied in the literature (36). Using the 
standard curve prepared with purified zeaxanthin diglucoside (Fig. D1), I calculated the 
yields from the crude extracts of each sample. Seven different media with 3 replicates 
were tested for the production of zeaxanthin diglucoside by Pseudomonas sp. 102515 in 














culture tubes. The LB, SOC and superbroth media showed better yields compared to the 
other media (Fig. D2). I then tried the LB, SOC and superbroth media in 50-mL flasks, 
resulting in a further improved production of zeaxanthin diglucoside. As shown in Fig. 
18A, SOC exhibited a relatively better yield (98 ± 7 mg/L).  
Glycerol was reported to enhance the yield of carotenoids (37). I thus tested the 
effects of glycerol on the production of zeaxanthin diglucoside in flasks at different 
concentrations (0.5%, 1% and 2% final concentration). The supplementation of 0.5% 
glycerol (final concentration) into the SOC medium increased the yield of zeaxanthin 
diglucoside to 127 ± 1.5 mg/ L after 3 days at 28 °C, representing a 30 % increase in the 
yield (Fig. 18B). I next tested how the cultivation time and temperature (18 °C, 23 °C, 28 
°C and 37 °C) affect the yield of zeaxanthin diglucoside in the SOC medium 
supplemented with 0.5% glycerol. The cultivation temperature of 37 °C resulted in 
extremely low yields (data not shown). Among the tested temperatures, 18 °C worked 
best and showed a yield of 206 ± 6 mg/L in the SOC medium after 5 days of cultivation 
(Fig. 18C). Under these conditions, I also tested the yields of zeaxanthin diglucoside in 
the engineered strains of E. coli BL21(DE3) and P. putida KT2440. Consistent with the 
cell colors, E. coli BL21(DE3) only produced 2 mg/L zeaxanthin diglucoside, while P. 
putida KT2440/pOKF192 generated the product in a much higher yield (121  6 mg/L). 
However, since this yield is still lower than the wild type (206 mg/L), the latter is a better 
starting strain for further improvements. I successfully engineered Pseudomonas sp. 
102515 by introducing pOKF192 into this strain, which allows this endophyte to have 




yield to 380 ± 12 mg/L after 5 days of incubation at 18 °C (Figs. 18C and 18D). 
 





FIG. 18. Optimization of zeaxanthin diglucoside production in Pseudomonas sp. 
102515. (A) The effect of culture media on the production of zeaxanthin diglucoside. (B) 
The effect of glycerol supplementation on the production of zeaxanthin diglucoside. (C) 
The effects of cultivation temperature and time on the production of zeaxanthin 
diglucoside by Pseudomonas sp. 102515 and Pseudomonas sp. 102515/pOKFF192. Cells 
were grown in 50 ml of SOC medium supplemented with 0.5% glycerol. (D) A 




102515 and three engineered strains. 
 
DISCUSSION 
Carotenoids with a huge market value play a significant role in maintaining good 
health and preventing human diseases including cardiovascular diseases, cancer and other 
chronic diseases due to their significant biological activities (38). Carotenoids are 
considered to protect cells from the damaging effects of reactive oxygen species (ROS), 
which are formed by normal metabolic activities and lifestyle factors such as diet, 
smoking and exercise. Carotenoids might potentially diminish the destructive effects of 
ROS such as superoxide (O2
−), hydrogen peroxide (H2O2), singlet oxygen (
1O2) and 
hydroxyl radical (OH) (39,40). In specific, 1O2 as a product in both biochemical and 
photochemical systems is reported to be responsible for the cell destruction caused by 
light and certain photosensitizers. The number of conjugated double bands in the 
carotenoids is a significant factor for the 1O2 quenching activity (41,42). Carotenoids 
such as lycopene, lutein, β-carotene, astaxanthin, and zeaxanthin are quite common in 
nature, however, glycosylated carotenoids such as dihydroxylycopene diglucoside, 
adonixanthin diglucoside and zeaxanthin diglucoside are very rare (43-46). Particularly, 
glycosylated carotenoids can be a potent antioxidant agent with protective properties 
against photooxidative damages from ROS and visible light (47,48). For instance, a novel 
glycosylated carotenoid, caloxanthin 3′-β-D-glucoside, was reported to have a potent 1O2 
quenching activity with an IC50 of 19 μM (49). Moreover, Tatsuzawa et al. reported that 




generation mixture compared to the cells that produce other carotenoids such as 
zeaxanthin, astaxanthin, β-carotene, and canthaxanthin (40). Glycosylated carotenoids are 
also reported to stabilize the membrane through integrating within the lipid membrane 
due to their polar functional groups (47,50). 
In this study, I isolated an endophytic bacterium Pseudomonas sp. 102515 from 
the leaves of Taxus chinensis, which was found to produce zeaxanthin diglucoside as a 
major metabolite. BLAST and phylogenetic analyses (Fig. 13) revealed that this 
endophytic isolate is a Pseudomonas strain. Pseudomonas species have been isolated 
from diverse sources including marine, freshwater, animals and plants (51-54). Certain 
Pseudomonas strains such as fluorescent Pseudomonads, are predominantly found in the 
rhizosphere and have been reported to move from rhizosphere to aerial plant tissue as in 
the case of P. aeurofaciens (55). Pseudomonas species were also reported as endophytes 
in the literature (56,57). For instance, P. stutzeri A15 is an endophytic nitrogen-fixing 
bacterium isolated from paddy rice (58). Another endophyte is P. fluorescens with 
beneficial interactions with plants (59). Plant-endophyte interactions have not been fully 
understood. However, many endophytes not only showed beneficial effects on their hosts, 
but also play a significant role in plant physiology. For example, some endophytic 
bacteria were reported to provide phytohormones, low-molecular compounds or enzymes 
to the host plants that led to the enhanced plant growth (60-62). Endophytic bacteria also 
provide an alternative way to manage plant pathogens as a promising biocontrol agent 
through various ways such as releasing antimicrobial substances, producing siderophores, 
and inducing the systemic resistance to pathogens (63-65). For instance, biological 




achieved by using an endophytic bacterium isolated from a medicinal plant (66).  
To better understand Pseudomonas sp. 102515, I looked into the closely related 
strains, P. psychrotolerans as well as P. oryzihabitans. Both strains were reported as 
yellow-pigmented gram-negative bacteria and isolated from different sources including 
clinical samples, cupper coins, diseased rice and rice seeds (67-71). An endophytic P. 
oryzihabitans strain isolated from Hibiscus rosasinensis was reported (72). P. 
psychrotolerans was isolated from copper coins, diseased rice and rice seeds as an 
endosymbiotic bacterium in two different studies (67,71). The later endophytic bacterium 
was reported to enhance the plant growth due to potential nitrogen fixing characteristics 
of the turnerbactin (tnb) biosynthetic gene cluster, which is responsible for the 
biosynthesis of turnerbactin, a tricatecholate siderophore. Plants infected with P. 
psychrotolerans PRS08-11306 showed enhanced growth (32,71). In this work, I also 
detected the tnb gene cluster and confirmed the existence of this gene cluster in 
Pseudomonas sp. 102515 by amplifying one of the key genes, tnbA. Thus, this endophyte 
also has a potential to be utilized as plant growth-promoting bacterium for agricultural 
applications. 
In addition to the tnb gene cluster, I found a complete carotenoid (Pscrt) 
biosynthetic gene cluster in Pseudomonas sp. 102515, which contains a series of 
carotenoid biosynthetic genes (Table 6). However, there are some differences in the 
organization of the genes between the Pscrt gene cluster and other reported ones (Fig. 
19). One obvious difference is the additional non-carotenoid gene (orf2) encoding for 
gluconate 2-dehydrogenase, which has not been reported in a carotenoid gene cluster to 




a crt biosynthetic gene cluster except crtZ have the same direction and are controlled by 
the same promoter in many γ-proteobacteria (34). However, the PscrtE gene has a 
different direction compared to most of the genes in the Pscrt gene cluster and is 
controlled by its own promoter (Fig. 19). The similar organization of crtE gene in the 
gene cluster was also reported in Pseudomonas sp. strain Akiakane isolated from the 
excrement of autumn darker, yet the crtZ gene in that gene cluster is located differently 
than ours and overlapped with the sequences of crtX and crtY as shown in Fig. 19 (54).  
 
 
FIG. 19. Organization of carotenoid biosynthetic gene clusters in the γ-
proteobacteria strains. NCBI accession numbers: M87280 for Pantoa agglomerans, 
CP001875 for Pantoa ananatis, and LC317091 and LC317092 for Pseudomonas sp. 
strain Akiakane. 
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I analyzed the functions of two Pscrt genes from Pseudomonas sp. 102515 
through heterologous expression of these genes with corresponding carotenoid-producing 
plasmids in E. coli BL21(DE3) (73,74). PsCrtI was confirmed to be a phytoene 
desaturase and PsCrtY is a lycopene cyclase. The function of the Pscrt gene cluster was 
characterized by expression of the entire biosynthetic gene cluster in two heterologous 
hosts, E. coli BL21(DE3) and P. putida KT2440, both yielding zeaxanthin diglucoside 
(Fig. 17). This heterologous expression strategy not only allows the functional 
confirmation of this gene cluster, but also provides an alternative way to produce 
zeaxanthin diglucoside. However, the yield of zeaxanthin diglucosde in E. coli was very 
low compared to Pseudomonas sp. 102515, likely due to the low efficiency of the native 
promoter in the this host. Sometimes a native promoters might not work well in a 
heterologous host. For instance, the phaC genes from P. putida were expressed in E. coli 
under the control of a native promoter or an external promoter. They were only expressed 
in E. coli with the external promoter (75). In another study, the levansucrase genes from 
P. syringae pv. glycinea PG4180 and P. syringae pv. phaseolicola NCPPB 1321 were 
cloned with the native promoters, yet the expression of levansucrase was only achieved 
upon the use of the lac promoter (76). Thus, heterologous expression of the Pscrt 
biosynthetic gene cluster from Pseudomonas sp. 102515 needs to be conducted using 
external promoters, in particular constitutive promoters, which might potentially enhance 
the production of zeaxanthin diglucoside in E. coli. Another approach is to choose 
another host microorganism. Since our isolate is a Pseudomonas strain, I proposed that 
the Pscrt gene cluster might be expressed better in P. putida KT2440 than E. coli. P. 




products including zeaxanthin (77,78). Our results confirmed that expression of the Pscrt 
gene cluster in P. putida KT2440 resulted in a much higher yield of zeaxanthin 
diglucoside than in E. coli (Fig. 18D). 
A common strategy to improve the yield is the optimization of culture conditions 
(79). I used LB medium for the isolation of Pseudomonas sp. 102515 and the initial 
product analysis of this endophyte. However, the nutrients in different media can affect 
the production of zeaxanthin diglucoside. A screening of 7 different media (Table D1) in 
culture tubes showed that LB, superbroth and SOC media had better yields ranging from 
13 to 15 mg/L (Fig. D2). I chose SOC medium for further optimization studies due to its 
higher titer in flasks (Fig. 18A) and found that 0.5 % glycerol supplementation further 
increased the yield to 127 ± 2 mg/L (Fig. 18B), which is consistent with a previous work 
on the effect of glycerol on the production of carotenoids (37). The effects of cultivation 
temperature and time were also examined. I originally used 28 °C as cultivation 
temperature as reported in the literature for the production of carotenoids (35,73,74,77). 
However, a comparison of four different temperatures revealed that 18 °C was the best 
cultivation temperature for the production of zeaxanthin diglucoside in Pseudomonas sp. 
102515. The yield reached 145 ± 5 mg/L in 50 mL of SOC medium. I then cultivated this 
endophyte in SOC medium supplemented with 0.5 % glycerol (final concentration) at 18 
°C for a week to find out the best fermentation time. Based on the time course analysis, 
the yield reached the highest (206 ± 6 mg/L) after 5 days of cultivation. However, low 
cultivation temperature is an economic burden for industrial production although it often 
favors the expression of enzymes (80). Therefore, I cultivated Pseudomonas sp. 102515 




18C). After 5 days of cultivation, I obtained a titer of 197 ± 8 mg/L that is slightly lower 
than but comparable to the titer at 18 C. Thus, 23 C can be used for industrial 
production of zeaxanthin diglucoside with Pseudomonas sp. 102515. To further improve 
the yield, I introduced pOKF192 carrying the Pscrt gene cluster into Pseudomonas sp. 
102515. With the additional copy of the Pscrt gene cluster, engineered Pseudomonas sp. 
102515/pOKF192 produced zeaxanthin diglucoside at 380 ± 12 mg/L at 18 C after 5 
days of cultivation, which is 85 % higher than the parent strain (Figs. 18C and 18D). 
Similar to Pseudomonas sp. 102515, this engineered strain at 23 C led to a slightly lower 
titer than but comparable to the titer at 18 C (Fig. 18C). To our knowledge, this study 
showed the highest yield of zeaxanthin diglucoside in bacteria.  
In conclusion, I isolated a carotenoid-producing endophytic Pseudomonas strain 
from the yew tree, which offers an alternative way to produce zeaxanthin diglucoside. A 
carotenoid biosynthetic gene cluster was identified in this endophyte, from which the 
functions of two Pscrt genes were confirmed in E. coli BL21(DE3). I also cloned the 
whole Pscrt gene cluster and successfully expressed it in two heterologous hosts, E. coli 
BL21(DE3) and P. putida KT2440. PCR analysis also showed that a turnerbactin 
biosynthetic gene cluster exists in the isolated strain, which will render our isolate a 
promising plant-growth promoting bacteria for agricultural applications. Additionally, I 
enhanced the yield of zeaxanthin diglucoside in the engineered endophytic isolate to 380 
± 12 mg/L by optimizing the culture conditions and introducing an additional copy of the 
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CHAPTER V SUMMARY AND ENGINEERING VALUE 
Summary of my dissertation research and future work 
My dissertation is focused on exploring the potential of bacteria for the 
biosynthesis of natural products with the purposes of creating novel natural product 
derivatives and of improving the production of pharmaceutically important natural 
products. In Chapter 2, I have investigated the glycosylation steps in the biosynthesis of 
two antifungal angucyclines from Streptomyces sp. SCC-2136, Sch47554 and Sch47555. 
Two different strategies were exploited for the characterization of three 
glycosyltransferases responsible for the glycosylation process. Co-expression of the 
aglycone and sugar biosynthetic genes with schS7 in S. lividans K4 led to the production 
of a novel C-glycosylated rabelomycin derivative, confirming that SchS7 is the dedicated 
C-glycosyltransferase. For schS9 and schS10, a gene disruption strategy was used to 
understand their functions in the glycosylation steps. Gene inactivation studies revealed 
that these glycosylation steps take place in a sequential manner in which SchS9 first 
attaches either a L-aculose or L-amicetose moiety to the 4'-OH of the C-glycosylated 
aglycone, and then SchS10 transfers a L-aculose moiety to the 3-OH of the angucycline 
core. In this research, I isolated two novel derivatives of angucycline and gained new 
insights into the glycosylation pathways in the biosynthesis of Sch47554 and Sch47555. 
In the future work, we can add additional glycosyltransferase genes cloned from similar 
biosynthetic gene clusters such as the landomycins and urdamycin biosynthetic gene 
clusters into our heterologous expression cassette to extend the sugar chain of the 




angucyclines, but also potentially enhance the biological activities of these angucyclines 
as reported in the literature (4).  
In Chapter 3, I worked on the same biosynthetic gene cluster for improved 
production of the angucyclines. The sch gene cluster includes several putative regulatory 
genes. schA4 and schA21 were predicted as the TetR family transcriptional regulators, 
whereas schA16 showed a significant similarity to the AraC family transcriptional 
regulators. I disrupted all of these regulatory genes in Streptomyces sp. SCC-2136. 
Disruption of schA4 and schA16 led to a significant increase in the production of 
Sch47554, while the titer was dramatically decreased in Streptomyces sp. SCC-
2136/ΔschA21. I also overexpressed them to further confirm their functional roles in the 
biosynthesis of angucyclines. Overexpression strains produced consistent results with the 
gene disruption strains. The highest titer of Sch47554 was achieved in Streptomyces sp. 
SCC-2136/ΔschA4 (27.94 mg/L), which is significantly higher than the wild type. Based 
on these results, I was able to characterize the functions of these three regulatory 
elements. SchA4 and SchA16 are repressors, while SchA21 acts as an activator. This 
work provided an initial understanding of functional roles of regulatory elements in the 
biosynthesis of Sch47554. Several efficient producing strains of Sch47554 were 
constructed by disrupting or overexpressing particular regulatory genes, which can be 
further engineered for industrial production of this medicinally important molecule. In the 
future work, a combination of the gene disruption with overexpression approaches might 
further enhance the titer of Sch47554. For instance, targeted gene deletion of schA4 
through double crossover recombination will result in a strain without any antibiotic 




to a far better yield of Sch47554. 
In Chapter 4, I isolated an endophytic bacterium from the leaves of Taxus 
chinensis. BLAST and phylogenetic analyses of the 16S rRNA sequence revealed that it 
is a Pseudomonas strain, named Pseudomonas sp. 102515. Based on the genome of a 
closely related Pseudomonas strain, a carotenoid (Pscrt) biosynthetic gene cluster was 
amplified from this endophyte. The functions of PsCrtI and PsCrtY were respectively 
identified as phytoene desaturase and lycopene cyclase in the biosynthesis of zeaxanthin 
diglucoside. The Pscrt biosynthetic gene cluster was successfully reconstituted in E. coli 
BL21(DE3) and Pseudomonas putida KT2440. The engineered strain of P. putida 
KT2440 produced zeaxanthin diglucoside at 144 ± 4 mg/L in the SOC medium 
supplemented with 0.5% glycerol at 23 C, while the titer of zeaxanthin diglucoside in E. 
coli BL21(DE3) was very low. The production of zeaxanthin diglucoside in 
Pseudomonas sp. 102515 was improved through the optimization of fermentation 
conditions. The highest titer under the optimized conditions reached 206 ± 6 mg/L. To 
further enhance the production, I introduced an expression plasmid that harbors the Pscrt 
biosynthetic gene cluster into Pseudomonas sp. 102515, yielding an efficient producing 
strain of zeaxanthin diglucoside. The titer in this engineered strain reached 380 ± 12 
mg/L, 85% higher than the wild type. Through PCR, I also discovered the presence of a 
turnerbactin biosynthetic gene cluster in Pseudomonas sp. 102515. Turnerbactin was 
reported to be involved in nitrogen fixation, which can promote the growth of host plants. 
Therefore, in addition to producing zeaxanthin diglucoside, Pseudomonas sp. 102515 




future work, the fermentation of engineered Pseudomonas sp. 102515 harboring 
pOKF192 in the bioreactor can be conducted to further enhance the titer of zeaxanthin 
diglucoside. The optimized fermentation conditions in the bioreactor such as dissolved 
oxygen, agitation speed and pH may lead to a further improved titer. 
Engineering value 
Engineered production of angucycline derivatives 
The heterologous expression approach helps researchers understand and engineer 
the biosynthetic pathways for creating structural diversity in natural products (5,6). In 
Chapter 2, I heterologously expressed some of the genes from the sch biosynthetic gene 
cluster, which yielded a novel angucycline derivative, C-glycosylated rabelomycin. I also 
disrupted two tailoring enzymes in the wild type strain, resulting in the isolation of 
another novel derivative of angucycline. These two strategies offer an effective platform 
to generate novel angucycline derivatives, which is quite useful for new drug 
development in the pharmaceutical industry. This study also provides new insights into 
the glycosylation steps in the biosynthesis of angucyclines, which can then be used to 
further engineer this biosynthetic pathway for generation of “unnatural” natural products. 
Engineered production of angucyclines in Streptomyces sp. SCC-2136 
Streptomyces sp. SCC-2136 produces two angucyclines, Sch47554 and Sch47555, 
which exhibit antifungal activity against various yeasts (Candida albicans, C. tropicalis 
and C. stellatoidea) and dermatophytes (Trichophyton mentagrophytes, T. rubrum, T. 




possess potent antitumor and antibacterial activities, as well as enzyme inhibitory and 
agonistic activities due to their structural similarity to other reported angucycline 
metabolites (8). Therefore, in Chapter 3, I attempted to enhance the titer of these 
compounds by strain engineering. In particular, the manipulation of regulatory genes 
through overexpression of activator genes and/or deletion of repressor genes has been 
successfully performed for improved production of natural products (9). I exploited these 
two strategies to create overexpression and gene disruption strains for three regulatory 
genes in the sch biosynthetic gene cluster. Two of the engineered strains showed 
significantly increased titers of Sch47554. The highest titer of Sch47554 was achieved in 
Streptomyces sp. SCC-2136/ΔschA4 (27.94 mg/L), which is much higher than the wild 
type (6.72 mg/L).  The overexpression of SchA21 in Streptomyces sp. SCC-2136 also 
improved the yield substantially to 26.23 mg/L. This work thus provides a more efficient 
way to produce this pharmaceutically important molecule (Sch47554). 
Engineered production of zeaxanthin diglucoside in Pseudomonas sp. 102515 
Carotenoids play a significant role in maintaining good health and preventing 
human diseases including cardiovascular diseases, cancer and other chronic diseases. 
These natural products possess a variety of  biological activities such as antioxidant, 
anticancer, and anti-inflammatory properties. They are also an important dietary source 
of vitamin A (10,11). Therefore, carotenoids have a huge market value. It was reported 
that the viability of zeaxanthin diglucoside producing E. coli cells is higher in the 1O2 
generation mixture compared to the cells that produce other carotenoids such as 




endophytic bacterium from the leaves of Taxus chinensis, which provides an alternative 
effective mean for the production of this promising antioxidant agent. I optimized the 
fermentation conditions of Pseudomonas sp. 102515 such as temperature, cultivation 
time, medium and glycerol supplementation. I achieved the highest yield of zeaxanthin 
diglucoside at 206 ± 6 mg/L in the SOC medium with glycerol supplementation after 5 
days of cultivation at 18 °C. With the introduction of an additional copy of the entire 
Pscrt gene cluster into Pseudomonas sp. 102515, I further increased the titer to 380 ± 12 
mg/L. This demonstrates that our strain is a promising microorganism for the production 
of pharmaceutically important antioxidant agent, zeaxanthin diglucoside. In addition, this 
isolate also has potential to be utilized as a plant growth-promoting bacterium for 
agricultural applications due to its turnerbactin biosynthetic capability, which enhances 
the nitrogen fixation capacity of host plants. 
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TABLE B1. Primers used in Chapter 2. 






























































glycosyltranferases including SimB7, LanGT2, SaqGT5, and UrdGT2. 
 
Fig. B1b. Clustal Omega amino acid sequence alignment of SchS9 with known O-
glycosyltranferases including LanGT1, SaqGT4, and UrdGT1c. 
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Fig. B1c. Clustal Omega amino acid sequence alignment of SchS10 with known O-
glycosyltranferases including LanGT4, SaqGT2, and UrdGT1a. 
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Fig. B2. ESI-MS spectrum of rabelomycin (1) with the [M+H]+ ion peak at m/z 339.0 and 

























Fig. B3a. 1H NMR for GG31 in (CD3)2CO, 300 MHz, JEOL ECX-300. 
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Fig. B3b. 13C NMR for GG31 in (CD3)2CO, 300 MHz, JEOL ECX-300. 
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Fig. B3c. HSQC NMR spectrum for GG31 in (CD3)2CO. 
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Fig. B4. ESI-MS spectrum of 3 with the [M-H]- ion peak at m/z 373.0, 4 with the [M-H]- 

























Fig. B5a. 1H NMR for urdamycin X in CD3OD, 500 MHz, Bruker AvanceIII HD 
Ascend-500. 
Fig. B5b. 1H NMR for 3'-deoxyaquayamycin in DMSO-d6, 500 MHz, Bruker AvanceIII 
HD Ascend-500). 





Fig. B5d. 13C NMR for OZK1 in CDCl3, 500 MHz, Bruker AvanceIII HD Ascend-500. 
 
Fig. B5e. HSQC NMR for OZK1 in CDCl3, 500 MHz, Bruker AvanceIII HD Ascend-
500. 
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Fig. B5f. HMBC NMR for OZK1 in CDCl3, 500 MHz, Bruker AvanceIII HD Ascend-
500.
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Fig. B6a. High resolution mass spectrum for GG31 with [M+H]+ at m/z 453.1561. 
Fig. B6b. High resolution mass spectrum for OZK1 with [M-H]- at m/z 583.2559. 
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APPENDIX C 
SUPPORTING INFORMATION for CHAPTER 3 
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Fig. C1. ESI-MS spectrum of Sch47544 (1) with the [M-H]- ion peak at m/z 689.1. 














Fig. C3. Confirmation of gene disruption of schA16 (A) and schA21 (B)  by PCR. 
A B













SUPPORTING INFORMATION for CHAPTER 4 
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TABLE D1. Recipes of the media used in Chapter 4. 
LB SOB SOC 2xYT TB 2xTB Superbroth 
Tyrptone (g/L) 10 20 20 16 12 24 32 
Yeast extract (g/L) 5 5 5 10 24 42 20 
NaCl (g/L) 10 0,58 0,58 5 - - 5 
Glycerol (ml/L) - - - - 4 15 - 
Phosphate buffer       
(0.17 M KH2PO4,       
0.72 M K2HPO4) (ml/L) 
- - - - 100 100 - 
KCl (g/L) - 1,9 1,9 - - - - 
MgCl2 (g/L) - 0,95 0,95 - - - - 
MgSO4 (g/L) - 1,21 1,21 - - - - 
Glucose (g/L) - - 3,6 - - - - 
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1 16S rRNA universal primer 8F-F1 ggctaccttgttacgacttc 
2 16S rRNA universal primer Rn1 agtttgatcctggctcag 
3 10-25-15-BGC-A-SpeI-NdeI-fw aactagtcatatgttggtggagatccgcgaggatcgcacc 
4 102515-A-NheI-rev tggccggcggcctgctagccctgcgcctggcccaaac 
5 102515-B-NheI-fw gccaggcgcagggctagcaggccgccggccaggccg 
6 10-25-15-BGC-B-PmeI-HindIII-rev2 aagtttaaacaagctttcaacgaggacgaaagacgatat 
7 BGC-A walker primer F1 catgtgctctgtcccaccgccg 
8 BGC-A walker primer R1 agggcttcttccgcctgctcaa 
9 BGC-A walker primer F2 tccttcggtttcctgctggcgc  
10 BGC-A walker primer R2 accaggcccggctggacgagca  
11 BGC-B walker primer F1 cagttggcgacaggcctgggcg 
12 BGC-B walker primer R1 catcagcagcggacgcagcc  
13 BGC-B walker primer F2 cttcgtcttcgcctccttcgg 
14 BGC-B walker primer R2 agcgtgctcgatgtcgccggaa  
15 Eho10-CrtX-NcoI-SmaI-fw aaccatggcccgggatgagccattttgccatt 




18 Eho10-CrtX-HindIII-rev aaaagctttcacgatacgctctcactccctgctatggc 
19 10-25-15-CrtI-NdeI-fw aacatatgatgacccaaggtaacgcgcccaagcgggccat 
20 10-25-15-CrtI-HindIII-rev aaaagctttcatggcttaccgtgctcctcgaggatgacgc 
21 10-25-15-CrtY-NdeI-fw aacatatgatgcgccctgacctgctgatcgtcgggggt 
22 10-25-15-CrtY-HindIII-rev aaaagctttcatggtgcttccttggactgagggggacgc 
23 Eho10-CrtX-NcoI-SmaI-fw aaccatggcccgggatgagccattttgccatt 
24 Eho10-CrtX-HindIII-rev aaaagctttcacgatacgctctcactccctgctatggc 
25 102515-TnbA-NdeI-fw aacatatgacgcaattggatttcaccggcaagcg 




Fig. D1. Standard curve for zeaxanthin diglucoside using UV spectrophotometer at 456 
nm. 
 
Fig. D2. The effects of different media on the yield of zeaxanthin diglucoside in the culture 
tubes (5mL).  
































OD value at 456 nm
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